Document:

Document

Exhibit 10.1

November 17, 2021

Diana Toman
Address on file with Company

Dear Diana:

This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of your separation from employment with Arconic Corporation and each of its parents, subsidiaries and affiliates (“Arconic” or the “Company”).  You and the Company agree as follows: 

1.Separation from Employment and Transition Services.  
a)By mutual agreement with the Company, and in consideration of the mutual promises and commitments set forth in this Agreement: you tendered, and the Company accepted, your resignation as Executive Vice President, Chief Legal Officer and Corporate Secretary on November 13, 2021 (“Notice Date”), and you will continue your employment in inactive status (on a leave of absence) while providing the Transition Services (as defined below) through December 31, 2021 (the “Transition Period”). Your employment and obligation to provide any Transition Services will end on December 31, 2021 (the “Separation Date”).
b)During the Transition Period (as defined below) you will answer questions and otherwise provide advisory services from time to time as may be reasonably requested by any executive officer of the Company, which may include legal and other advice similar to that provided by Executive previously when engaged as an active employee of the Company (the “Transition Services”).   You shall not accrue any further rights to vacation, equity or bonus compensation during the period between the Notice Period and the Separation Date.
c)You agree that if you accept employment with another employer and such employment is to begin prior to December 31, 2021, you will inform the Company and, in such event,  your Separation Date will be made effective as of the date prior to your beginning such new employment and, provided you execute and do not revoke the supplemental release referenced in Paragraph 2(b), and you have otherwise complied with your obligations under this Agreement, you shall receive the payments and benefits set forth in Paragraph 2(b). 
d)Regardless of whether you have timely executed and not revoked this Agreement and otherwise comply with its terms, you shall receive the following:
i)The Company has paid or will pay you in accordance with the Company’s reimbursement policy for all business expenses which you properly incurred in connection with your work for the Company through the Notice Date.
ii)The Company has paid or will pay your base salary through the Notice Date.
2.Consideration.  
a)Provided that you have timely executed and not revoked this Agreement and otherwise comply with its terms, you shall receive the following consideration:
i)Your employment will be continued in inactive status through December 31, 2021.  During the time period between the Notice Date and Separation 
1

Date (“Transition Period”), you shall continue to receive your current base salary (in effect as of November 12, 2021) and benefits in accordance with the Company’s normal practices, policies, and plans; 
ii)A single cash payment in the amount of five hundred twenty-five thousand dollars and zero cents ($525,000.00), which represents a further separation payment from the Company, payable on December 31, 2021, unless such other payment date is required pursuant to Section 409A; provided, however, that if you do not timely execute, or if you timely execute and then effectively revoke the release attached as Exhibit B (in accordance with Paragraph 2(b) below), you agree to immediately repay to the Company the net sum of $262,500.00, and you further agree that your retention of the remaining amount of this further separation payment, together with the other payments, benefits and commitments by the Company as provided for in this Agreement, are sufficient consideration for the continued enforceability of your waiver and release and other obligations set forth in this Agreement; and 
iii)You shall be eligible to receive the payments and benefits set forth in Paragraph 2(b). 
b)Provided this Agreement has become effective in accordance with its terms, and provided further that you timely execute and do not revoke the release attached as Exhibit B (which must be executed on, but not before, the Separation Date) and otherwise comply with your commitments and obligations under this Agreement and Exhibit B, you shall receive the following additional separation benefits:
i)A single cash payment in the amount of eight hundred eighty-five thousand five hundred dollars and zero cents ($885,500.00), which represents one times the sum of your annual base salary and your target annual cash incentive compensation, payable within thirty (30) days of your Separation Date, unless such other payment date is required pursuant to Section 409A of the Internal Revenue Code (“Section 409A”); and
ii)During the twenty-four (24) month period following your Separation Date, the Company shall arrange (via COBRA or otherwise) to provide you and anyone entitled to claim through your life, accident and health (including medical, behavioral, prescription drug, dental and vision) benefits substantially similar to those provided to you and anyone entitled to claim through you immediately prior to your Separation Date, at no greater after-tax cost to you than the after-tax cost to you immediately prior to such Separation Date.
c)All payments set forth in this Paragraph 2 shall be paid by the Company less applicable taxes, withholdings, and other deductions and are subject to compliance with Section 409A.
3.Release.  
a)In consideration of the payments, benefits, and other items of value set forth in Paragraph 2(a) hereof and your eligibility to receive the additional payments, benefits, and other items of value pursuant to Paragraph 2(b), and the other promises and consideration provided by the Company hereunder, to the fullest extent permitted by law, you waive, release, and forever discharge the Company and each of its past and current parents, subsidiaries, affiliates, and each of its and their respective past and current directors, officers, trustees, employees, representatives, agents, employee benefit plans and such plans’ administrators, fiduciaries, trustees, recordkeepers and service providers, and each of its and their 
2

respective successors and assigns, each and all of them in their personal and representative capacities (collectively the “Company Releasees”) from any and all claims legally capable of being waived, grievances, injuries, controversies, agreements, covenants, promises, debts, accounts, actions, causes of action, suits, arbitrations, sums of money, attorneys’ fees, costs, damages, or any right to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance, or common law, which you now have, ever have had, or may hereafter have, based upon or arising from any fact or set of facts, whether known or unknown to you, from the beginning of time until the date of execution of this Agreement, arising out of or relating in any way to your employment relationship with the Company or the Company Releasees or other associations with the Company or the Company Releasees or any termination thereof.  Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right, to the extent legally capable of being waived, based upon or arising under any federal, state, or local fair employment practices or equal opportunity laws, including, but not limited to, Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §§ 2000e, et seq. (“Title VII”); the Equal Pay Act of 1963, 29 U.S.C. § 206(d) (the “Equal Pay Act” or “EPA”); the Americans with Disabilities Act, 29 U.S.C. § 12101 et seq. (“ADA”); the Employee Retirement Income Security Act of 1974, 29 U.S.C. §§ 1001, et seq. (“ERISA”) (except for vested benefits otherwise entitled); the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq. (“ADEA”); the Older Workers’ Benefits Protection Act (“OWBPA”); the Family and Medical Leave Act of 1993, including all amendments thereto; the Pennsylvania Human Relations Act, including age and sexual harassment claims; the Pennsylvania Equal Pay Law; the Pennsylvania Whistleblower Law; the Pennsylvania Pregnancy Guidelines of the Pennsylvania Human Relations Commission; Kansas Act Against Discrimination, including age and sexual harassment claims; Kansas Equal Pay Law; Kansas Age Discrimination in Employment Act; Kansas Discrimination Against Military Personnel Act; Kansas Discrimination Against Victims of Domestic Violence or Sexual Assault Act; Kansas’ whistleblower protection laws (including Kan. Stat. Ann. §§ 39-1403, 39-1432, 44-615 & 44-636); Kansas Minimum Wage and Maximum Hours Law; Kansas WARN Act; any federal, state, local, and/or municipal statute, law, amendment, directive, order, and/or regulation enacted in response to the COVID-19 pandemic; and any other federal, state, or local statutes, common law, or regulation, including any and all amendments to the foregoing.
b)You also agree to waive any right to bring, maintain, or participate in a class action, collective action, or representative action against the Company and/or the Company Releasees to the fullest extent permitted by law.  You agree that you may not serve as a representative of a class action, collective action, or representative action, may not participate as a member of a class action, collective action, or representative action, and may not recover any relief from a class action, collective action, or representative action.  You further agree that if you are included within a class action, collective action, or representative action, you will take all steps necessary to opt-out of the action or refrain from opting in, as the case may be.  You are not waiving any right to challenge the validity of this Paragraph 3(b) on any grounds that may exist in law and equity.  However, the Company and the Company Releasees reserve the right to attempt to enforce this Agreement, including this Paragraph 3(b), in any appropriate forum.
c)Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or prevents you  from making or asserting: (i) any 
3

claim or right you may have under COBRA; (ii) any claim or right you may have for unemployment insurance or workers’ compensation benefits; (iii) any claim to vested benefits under the written terms of a qualified employee pension benefit plan; (iv) any medical claim incurred during your employment that is payable under applicable medical plans or an employer-insured liability plan; (v) any claim or right that may arise after the execution of this Agreement; (vi) any claim or right you may have under this Agreement; (vii) any claim to indemnification under your Indemnification Agreement with the Company; (viii) any claim that is not otherwise waivable under applicable law; or (ix) any claim that you may have as a shareholder or equity owner of the Company.  In addition, nothing herein shall prevent you from filing a charge or complaint with the Equal Employment Opportunity Commission (“EEOC”) or similar federal or state agency or your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that pursuant to Paragraph 3(a), you are waiving any right to recover monetary damages or any other form of personal relief in connection with any such charge, complaint, investigation, or proceeding. To the extent you receive any personal or monetary relief in connection with any such EEOC charge, complaint, investigation, or proceeding, the Company will be entitled to an offset for the consideration made pursuant to Paragraph 2 of this Agreement.  
4.Violations of Any Law or of the Company’s Code of Conduct.  You hereby agree, promise and covenant that during your employment with the Company: (i) you did not intentionally or knowingly violate any federal, state, or local law, statute, or regulation while acting within the scope of your employment with the Company; and (ii) you did not intentionally or knowingly violate any material provision of the Company’s Code of Conduct while acting within the scope of your employment with the Company (collectively, “Violations”).
5.Return of Property.  On or before the Separation Date, you agree, at the Company’s expense, to (i) promptly return to the Company all of its property, including, but not limited to, computer, iPad, cell phone, identification card, credit card, and keys, and (ii) shred any paper files or documents within your possession prior to the Separation Date, unless otherwise agreed.  To the extent you have any Company information or property stored on any personal computer, personal laptop, iPad, cloud storage, personal email account, or any other personal device, you agree to cooperate with the Company to permanently delete any such information or property from such devices, subject to any legal duty to preserve and retain such information. 
6.No Additional Entitlements.  You agree that other than the payments described in Paragraph 2 (as applicable): (i) you have received all entitlements due from the Company relating to your employment with the Company including, but not limited to, all wages earned, sick pay, bonuses, overtime pay, and any paid and unpaid personal leave for which you were eligible and entitled, and that no other entitlements are due to you other than as set forth in this Agreement and Exhibit B (as applicable); and (ii) you further acknowledge and agree that, other than as expressly set forth in this Agreement, you are not entitled to and shall not receive any further payments, compensation, or benefits under this Agreement or Exhibit B or under any other prior agreement with the Company or any of its subsidiaries including, but not limited to, any payments or compensation relating to any Restricted Stock Units or any payments, compensation, or benefits under the Arconic Corporation Executive Severance Plan.  For the avoidance of doubt, (i) you hereby waive any entitlement to, and you shall not receive any payment for, any unused and accrued vacation through the Separation Date and acknowledge that the payments set forth in Paragraph 2(b) include any payment therefore; and (ii) all unvested equity related awards (e.g., stock options, restricted stock units) shall be forfeited and no payment shall be made with respect thereto, and any equity related awards vested as of the Separation 
4

Date (e.g., options) shall remain subject to the terms and conditions of the applicable plan and award agreement(s).
7.[Reserved] 
8.Cooperation. You agree to reasonably cooperate with the Company (including its officers, their designees, or legal counsel) by providing all information that the Company may reasonably request with respect to matters involving the work you performed for the Company and your responsibilities and duties during your employment with the Company, as well as with respect to any litigation, investigation, or other legal proceeding involving the Company, so long as such requests do not unreasonably interfere with or create a legal conflict of interest with any other employment or work in which you are engaged.  You agree to appear without the necessity of a subpoena to testify truthfully in any litigation, investigation, or other legal proceedings in which the Company calls you as a witness, provided that you are provided reasonable notice and access to relevant historical files and email if necessary for your cooperation, and such appearance does not cause you any undue burden, expense, or harm.  In connection with fulfilling your obligations under this Paragraph, your pre-approved, reasonable, documented out-of-pocket expenses will be reimbursed by the Company (including travel expenses and attorneys’ fees).  In the event that such cooperation is requested following the period of one (1) year after your Separation Date, you and the Company shall confer with respect to a mutually agreeable and reasonable hourly consulting rate.  You shall continue to be entitled to all benefits, indemnification, advancement rights, and protections provided for in your Indemnification Agreement and to the fullest extent permitted by law and applicable insurance policy, which shall extend to any post-termination consulting provided to the Company.
9.Confidentiality of the Agreement.  Except as expressly permitted in Paragraph  12 of  this Agreement or if otherwise required by law, the parties, including you and the Company Releasees, shall not disclose the existence of this Agreement, the terms of this Agreement, or the circumstances giving rise to this Agreement, to any person other than their respective attorneys, immediate family members, accountants, financial advisors, or corporate employees who have a business need to know such terms in order to approve or implement such terms.
10.Protection of Confidential Information.  Except as expressly permitted in Paragraph 12 of this Agreement or if otherwise required by law:
a)You hereby acknowledge and agree to comply with your ongoing obligations as set forth in the Confidentiality, Non-Competition, and Non-Solicitation Agreement (attached hereto as Exhibit A), the terms of which are hereby incorporated into this Agreement, as well as your obligations to maintain the confidentiality of the Company’s information as set forth in the Company’s Code of Conduct.  Notwithstanding the foregoing, the Non-Competition provision of Exhibit A shall not preclude you from obtaining future employment in an in-house attorney position with a Competitive Business (as defined in Exhibit A), and in such position having responsibility for the oversight of other administrative functions, such as compliance, environmental, health, safety, security, government affairs, community engagement, trade compliance or human resources. 
b)Without limiting the generality of the foregoing obligations set forth in Paragraph 10(a), you agree that you will not at any time, directly or indirectly, disclose any trade secret, confidential or proprietary information you have learned by reason of your association with the Company (the “Confidential Information”) and your continued cooperation under Paragraph 8 or use any such Confidential Information to the detriment of the Company, its parents, affiliates, or 
5

subsidiaries, or to the benefit of any business or enterprise that competes with the Company, its parents, affiliates, or subsidiaries.  Confidential Information is deemed to include, but is not limited to, information pertaining to Company strategic plans, advertising and marketing plans, sales plans, formulae, processes, methods, machines, ideas, concepts, new product developments, proposed launches, discontinuance of existing products, product and consumer testing data, sales and market research, technology research and development, budgets, profit and loss data, raw material costs, identity of suppliers, customer lists, customer information, non-public information about employees that is maintained as confidential by the Company,  improvements, inventions, and associations with other organizations that the Company has not previously made public.  Confidential Information does not include (i) information that can be shown by written evidence to be in the public domain at the time of disclosure by you, (ii) information that was developed by another party without reference to the Confidential Information or (iii) information that is publicized or otherwise becomes part of the public domain through no fault of your own.
c)You acknowledge that in the course of your employment with the Company, you have acquired and/or had access to non-public information and material including privileged information relating to litigation involving the Company and/or the resolution or settlement thereof, privileged internal and/or external investigations and regulatory matters, attorney-client communications, communications with outside counsel, and other Company legal matters, all of which are subject to and protected from disclosure by the attorney-client privilege, attorney work product doctrine, and/or any other applicable privileges (referred to collectively as “Privileged Information”).  You acknowledge and agree that such Privileged Information (including any underlying privilege therein) belongs exclusively to the Company, and that the Company has not waived any such underlying privilege.
11.Non-Disparagement/Separation Communications.  Subject to Paragraph 12, and further subject to the Company’s SEC reporting obligations:
a)You agree that you shall not publish or communicate, or cause, direct, induce, or encourage any other person, entity, or other third party to make, publish, or communicate, whether anonymously or not, any statement, observation, opinion, or information, whether verbal or written, of a defamatory or disparaging nature regarding the Company and/or the Company Releasees or their personnel or products and you shall not take any action that would cause the Company and/or the Company Releasees or their personnel or products any embarrassment or humiliation or otherwise cause or contribute to their being held in disrepute. The Company will only provide anyone who inquiries about your employment instructions on how to call The Work Number for official employment verification.
b)The Company will instruct in writing Timothy Myers, Melissa Miller, and any future authorized Company spokesperson to not publish or communicate, or cause, direct, induce, or encourage any other person, entity or other third party to make, publish or communicate, whether anonymously or not, any statement, observation, opinion or information, whether verbal or written, of a defamatory or disparaging nature about you or take any action that would cause you any embarrassment or humiliation or cause or contribute to you being held in disrepute.
c)You and the Company agree to respond to questions regarding your resignation and separation as set forth in Exhibit C hereto.
6

12.Permitted Conduct.    Nothing in this Agreement or Exhibit B (as applicable) shall prohibit or restrict the Company or you from lawfully (A) initiating communications directly with, cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency, entity, or official(s) (collectively, “Governmental Authorities”) regarding a possible violation of any law; (B) responding to any inquiry or legal process directed to you individually (and not directed to the Company and/or its subsidiaries) or to the Company from any such Governmental Authorities; (C) testifying, participating, or otherwise assisting in an action or proceeding by any such Governmental Authorities relating to a possible violation of law; or (D) making any other disclosures that are required by law or protected under the whistleblower provisions of any applicable law.  You may also disclose the requirements of Paragraph 8 to a future employer.   Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to your attorney in relation to a lawsuit for retaliation against you for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  Nor does this Agreement require you to obtain prior authorization from the Company before engaging in any conduct described in this paragraph, or to notify the Company that you have engaged in any such conduct.  Nor does this Agreement require the Company to obtain prior authorization from you before engaging in any conduct described in this paragraph, or to notify you that the Company has engaged in any such conduct.  Other than as provided in Paragraph 3(c), nothing in this Agreement shall prohibit you from receiving an award for information provided to any government agency in accordance with this Paragraph.
13.Non-Admission.  It is understood and agreed that neither the execution of this Agreement, nor the terms of the Agreement, constitute an admission of liability to you by the Company or the Company Releasees, and such liability is expressly denied.  It is further understood and agreed that no person shall use the Agreement, or the consideration paid pursuant thereto, as evidence of an admission of liability, inasmuch as such liability is expressly denied.
14.No Obligation to Re-Hire.  You acknowledge and understand that your employment relationship with the Company will permanently end as of the Separation Date and that neither the Company nor any of its parents, subsidiaries, affiliates, or related companies will be obligated to rehire you or to consider you for reemployment after the Separation Date.  
15.Acknowledgments.  You hereby acknowledge that: 
a)The Company advises you to consult with an attorney before signing this Agreement; 
b)You have obtained independent legal advice from an attorney of your own choice with respect to this Agreement and all exhibits, or you have knowingly and voluntarily chosen not to do so;  
c)You freely, voluntarily and knowingly entered into this Agreement after due consideration;  
d)You have had a minimum of twenty-one (21) days to review and consider this Agreement and all exhibits;
7

e)If you knowingly and voluntarily choose to do so, you may accept the terms of this Agreement before the twenty-one (21) day consideration period provided for in Paragraph 15(d) above has expired;
f)You and the Company agree that changes to the Company’s offer contained in this Agreement, whether material or immaterial, will not restart the twenty-one (21) day consideration period provided for in Paragraph 15(d) above;
g)You have a right to revoke this Agreement by notifying the undersigned Company representative in writing, via hand delivery, facsimile, or electronic mail, within seven (7) days of your execution of this Agreement; 
h)In exchange for your waivers, releases, and commitments set forth herein, including your waiver and release of all claims arising under the Age Discrimination in Employment Act, the payments, benefits, and other considerations that you are receiving pursuant to this Agreement and Exhibit B (as applicable) exceed any payment, benefit, or other thing of value to which you would otherwise be entitled, and are just and sufficient consideration for the waivers, releases, and commitments set forth herein; and
i)No promise or inducement has been offered to you, except as expressly set forth herein, and you are not relying upon any such promise or inducement in entering into this Agreement.  Your employment remains at-will and this Agreement does not confer upon you any right or obligation to continue in the employ of the Company for any period of time.
16.Revocation by the Company.  You agree that if you fail to execute and return this Agreement to the Company within the time specified herein for your review and consideration, or if you timely execute and then effectively revoke this Agreement, the promises and agreements made by the Company herein will be revoked and your separation from the Company shall be made immediately effective. 
17.Miscellaneous.
a)Entire Agreement.  This Agreement, including all exhibits, sets forth the entire agreement between you and the Company and replaces any other oral or written agreement between you and the Company relating to the subject matter of this Agreement, except for your prior obligations of confidentiality as provided for in Paragraph 10 above and your obligations under the Confidentiality, Non-Competition, and Non-Solicitation Agreement attached hereto as Exhibit A, as amended, which shall continue in full force and effect.
b)Governing Law.  This Agreement shall be construed, performed, enforced and in all respects governed in accordance with the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof.  Additionally, all disputes arising from or related to this Agreement shall be brought in a state or federal court situated in the State of Delaware, and the parties hereby expressly consent to the jurisdiction of such courts for all purposes related to resolving such disputes.
c)Severability.  Should any provision of this Agreement, including all exhibits, be held to be void or unenforceable, the remaining provisions shall remain in full force and effect, to be read and construed as if the void or unenforceable provisions were originally deleted. 
d)Amendments.  This Agreement may not be modified or amended, except upon the express written consent of both you and the Company.  
8

e)Breach.  You acknowledge that if you breach your commitments to the Company agreed upon in Paragraphs 4, 5, 7, 8, 9, 10 and/or 11 and pursuant to Exhibit A, you will forfeit the consideration set forth in Paragraph 2(a) and your eligibility to receive any consideration pursuant to Paragraph 2(b), and be subject to suit by the Company for damages and equitable relief relating to such breach.
f)Waiver.  A waiver by either party hereto of a breach of any term or provision of the Agreement shall not be construed as a waiver of any subsequent breach.
g)Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement.
h)Effective Date.  This Agreement shall become effective upon the expiration of the seven (7) day revocation period provided for in Paragraph 15(g) above. 
18.Compliance with Code Section 409A.  The amounts payable under this Agreement are intended to comply with the “short term deferral” exception from Section 409A of the Internal Revenue Code specified in Treas. Reg. § 1.409A-1(b)(4) (or any successor provision) or the separation pay plan exception specified in Treas. Reg. § 1.409A-1(b)(9) (or any successor provision), or both of them, and shall be interpreted in a manner consistent with those exceptions. Notwithstanding the foregoing, to the extent that any amounts payable in accordance with this Agreement are subject to Section 409A, this Agreement shall be interpreted and administered in such a way as to comply with the applicable provisions of Section 409A to the maximum extent possible.  To the extent that this Agreement is subject to Section 409A and fails to comply with the requirements of Section 409A, the Company reserves the right (without any obligation to do so) to amend, restructure, terminate or replace this Agreement in order to cause this Agreement either to comply with the applicable provisions of Section 409A or not be subject to Section 409A.  If payment of any amount of “deferred compensation” (as defined under Section 409A) is triggered by a separation from service that occurs while you are a “specified employee” (as defined under Section 409A)  with respect to Company, and if such amount is scheduled to be paid within six (6) months after such separation from service, the amount shall accrue without interest and shall be paid the first business day after the end of such six-month period, or, if earlier, within 15 days after the appointment of the personal representative or executor of the your estate following your death.  Each payment of compensation under the Agreement shall be treated as a separate payment of compensation for purposes of applying Section 409A. “Termination of employment,” “retirement,” “resignation” or words of similar import, as used in this Agreement shall mean, with respect to any payments of deferred compensation subject to Section 409A of the Code, your “separation from service” as defined in Section 409A. You shall not have the ability to control, directly or indirectly, the timing of any payments of deferred compensation subject to Section 409A. Any payments that are deferred compensation subject to Section 409A, and that could occur in one of two calendar years depending on the timing of an action by you, such as the delivery of a release, will always occur in the later year. Nothing in this Agreement shall be construed as a guarantee of any particular tax treatment to Employee.  You are solely responsible for the tax consequences with respect to all amounts payable under this Agreement, and in no event shall the Company have any responsibility or liability if this Agreement does not meet any applicable requirements of Section 409A.   

If the above accurately states our agreement, including the separation, waiver and release, kindly sign below and return the original Agreement to me.  I will sign it and return a copy to you.  

                    
9

Sincerely,

                    ARCONIC CORPORATION

                    By: /s/ Tim Myers            
                          Tim Myers
                          Chief Executive Officer

                    Date: November 17, 2021        

                    UNDERSTOOD, AGREED TO
                    AND ACCEPTED WITH THE
                    INTENTION TO BE LEGALLY BOUND:

                    /s/ Diana C. Toman            
                    DIANA TOMAN

                    Date: November 17, 2021        

Enclosures

10

EXHIBIT A

Confidentiality, Developments, Non-Competition, and Non-Solicitation Agreement

As an employee of Arconic Inc. (“Arconic”) or one of its subsidiaries (Arconic collectively with its subsidiaries, the “Company”), you (“you” or “Employee”) will have access to or may develop confidential and proprietary information (as defined below) of the Company.  Therefore, in consideration of your employment, and recognizing the highly competitive nature of the Company’s business, you enter into this Confidentiality, Non-Competition, and Non-Solicitation Agreement (this “Agreement”) intending to be legally bound.

Confidentiality

You acknowledge that, as an employee of the Company, you have access, and are privy, to information which is confidential and proprietary to the Company and which is not generally available to the public from sources outside of the Company.  

You agree to regard and preserve as confidential any and all Confidential Information pertaining to the Company’s operations and affairs and all information which is either learned or obtained by you during your employment, and which you know, or have reason to believe, includes Confidential Information.  You agree that you will use Confidential Information only for the performance of your duties for the Company and you agree not to disclose any Confidential Information you acquire, except as expressly permitted below.  You understand and agree that this obligation of confidentiality shall continue indefinitely following the termination of your employment with the Company.  

Nothing in this Agreement shall prohibit or restrict you from: (i) making any disclosure of relevant and necessary information or documents in any action, investigation, or proceeding relating to this Agreement, or as required by law or legal process; or (ii) participating, cooperating, or testifying in any action, investigation, or proceeding with, or reporting possible violations or providing information to, any governmental agency or legislative body regarding this Agreement or the Company, including, but not limited to, the Company’s Legal Department, the Securities & Exchange Commission, and/or pursuant to the Dodd-Frank Act (including without limitations the whistleblower provisions thereof) or Sarbanes-Oxley Act; provided that, other than with respect to providing information to a governmental agency and to the extent permitted by law, upon receipt of any subpoena, court order or other legal process compelling the disclosure of any such information or documents, you will give the General Counsel of the Company prompt written notice so as to permit the Company to protect its interests in confidentiality to the fullest extent possible.   Notwithstanding any provision of this Agreement to the contrary, the provisions of this Agreement are not intended to, and shall be interpreted in a manner that does not, limit or restrict you from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Securities Exchange Act of 1934, as amended).

Upon termination of your employment or at any time requested by the Company, you will deliver promptly to the Company all memoranda, notes, records, reports and other documents (whether in paper or electronic form and all copies thereof) relating to the business of the Company and all other Company property which you obtained or developed while employed by, or otherwise serving or acting on behalf of, the Company and which you may then possess or have under your control, whether directly or indirectly.

Disclosure of Developments and Other Inventions 

Without disclosing any third party confidential information, Employee shall promptly disclose to Company all Developments and any inventions or developments that Employee believes do not constitute a Development, so that Company can make an independent 

assessment.  Employee represents and warrants that if Employee developed, conceived or created any Development or other Intellectual Property prior to the date hereof that relates to Company’s Business, Employee has listed such Intellectual Property on Appendix 1 in a manner that does not violate any third party rights or disclose any third party confidential information.

Ownership of Developments

Ownership:  All right, title and interest (including all Intellectual Property rights of any sort throughout the world) relating to any and all Developments (other than Employee Statutorily Exempt Developments) shall be the exclusive property of Company. 

Assignment of Rights: In consideration of Employee’s employment by Company as set forth in the Employment Agreement, Employee hereby assigns to Company or its designee any and all right, title and/or interest (including all Intellectual Property rights of any sort throughout the world) in and to any Developments that Employee has or may in the future acquire with respect to any Developments, provided that this section shall not apply to any Employee Statutorily Exempt Developments.  

Further Assistance and Assurances:  Employee shall, both during and after his/her employment by Company, at the expense of Company, perform all lawful acts requested by, or on behalf of, Company to enable Company to obtain, perfect, sustain, and enforce its ownership interest in any Development(s) in accordance with this Section and to obtain and maintain patents, copyrights and other Intellectual Property rights for such Development(s) throughout the world. 

Attorney-In-Fact:  Employee hereby irrevocably designates and appoints Company as Employee’s agent and attorney-in-fact, coupled with an interest and with full power of substitution, to act for and on Employee’s behalf to execute and file any document and to do all other lawfully permitted acts to further the purposes of this Section with the same legal force and effect as if executed by Employee.  

Acknowledgement of Employee Statutorily Exempt Developments:  Employee acknowledges and agrees that, by executing this Agreement, nothing in this Agreement is intended to expand the scope of protection provided to Employee by Sections 2870 through 2872 of the California Labor Code or any other statute of like effect.  Employee agrees to promptly advise the Company in writing of any developments that Employee believes may qualify under Sections 2870 through 2872 of the California Labor Code or any other statute of like effect.

Records:  Employee agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings, and in any other form that may be required by the Company) of all Developments made, written, conceived and/or reduced to practice by Employee during the period of employment by Company, which records shall be available to and remain the sole property of the Company at all times.

Employee IP – Ownership and Restrictions; License:  Any discovery, invention, improvement, computer program and related documentation or other work that (i) is created during the term of Employee’s employment with the Company and does not fall within the definition of the term “Development” as defined herein, (ii) is an Employee Statutorily Exempt Development, or (iii) was developed, created, or conceived prior to Employee’s employment with Company shall, as between Company and Employee, belong to Employee and shall not be used by Employee in his or her performance on behalf of the Company.  Without limiting Company’s other rights and remedies, if, when acting within the scope of Employee’s employment or otherwise on behalf of Company, Employee uses or discloses Employee’s own or any third party’s confidential information or other Intellectual Property in violation of this Agreement (or if any Development cannot be fully made, used, reproduced, distributed and 

otherwise exploited without using or violating the foregoing), Employee hereby:  (a) grants to Company a perpetual, irrevocable, worldwide, fully-paid, royalty-free, non-exclusive, sub-licensable right and license to use, exploit and exercise all such confidential information and/or Intellectual Property rights; and (b) warrants that he/she is entitled to grant such license to the extent the confidential information or Intellectual Property used by Employee in violation of this Section belongs to a third party.

Restrictive Covenants

    Non-Competition:  During your employment and for a period of one year thereafter (regardless of whether the termination of your employment is voluntary or involuntary), you will not directly or indirectly (i) engage in, carry on, or provide services (paid or unpaid) whether as a director, officer, partner, owner, employee, inventor, consultant, advisor, or agent, to any Competitive Business (as defined below) or (ii) hold any economic interest in any Competitive Business.  However, notwithstanding the foregoing, you may own up to five percent (5%) of the outstanding securities of any publicly traded company and you shall not be prohibited from becoming employed by, or associated with, a private equity firm or hedge fund (or one of their portfolio companies) that has an investment in a Competitive Business as long as you have no involvement whatsoever with such Competitive Business (including the formation, planning, or acquisition of, or investment in, any such Competitive Business).

It is not the Company’s intention to restrict or limit your activities following your termination of employment with the Company unless it is believed that there is a substantial possibility that your future services or activities in any of the lines of business in which the Company is engaged may be detrimental to the Company.  So as to not unduly restrict your future employment, if you desire to enter into any employment arrangement or relationship with any potential Competitive Business within the one-year restricted period, please consult with the Executive Vice President of Human Resources of Arconic/Howmet to discuss your intended relationship with the entity.  Due to the many different businesses in which the Company presently engages, or which in the future the Company may engage, we will discuss your desire to enter into a business or professional relationship with any manufacturer or firm which is a Competitive Business.  The Company’s consent will not be unreasonably withheld.

Also, as a reminder, Arconic/Howmet stock incentive awards continue to be subject to forfeiture, under the terms of that program, to the extent you become associated with, employed by, render services to, or own any interest in any business that is in competition with the Company or if you engage in willful conduct that is injurious to the Company.

Non-Solicitation:  During your employment and for a period of one year thereafter (regardless of whether the termination of your employment was voluntary or involuntary), you will not directly or indirectly (i) solicit, induce or attempt to solicit or induce any employee of the Company to leave the Company for any reason; (ii) hire or attempt to hire any employee of the Company; or (iii) solicit business from, or engage in business with, any customer or supplier of the Company that you met and/or dealt with during your employment with the Company for any purpose.  In the event that you become aware that any employee of the Company has been hired by any business or firm with which you are then affiliated, you will immediately notify the Executive Vice President of Human Resources of Arconic/Howmet to confirm your non-solicitation of said employee

You acknowledge and agree that given the nature of the Company’s business, which is conducted throughout the world, the unique and extraordinary services you will be providing to the Company and your position of confidence and trust with the Company, the scope and duration of the covenants included in this Agreement (the “Restrictive Covenants”) are reasonable and necessary to protect the legitimate business interests of the Company.  You 

further acknowledge that you have received substantial consideration from the Company and that your general skills and abilities are such that you can be gainfully employed in noncompetitive employment, and that this Agreement will in no way prevent you from earning a living following your employment with the Company.

You also recognize and agree that any breach or threatened or anticipated breach of any part of these Restrictive Covenants will result in irreparable harm to the Company, and that the remedy at law for any such breach or threatened breach will be inadequate.  Accordingly, in addition to any other legal or equitable remedies that may be available to the Company, you agree that the Company will be entitled to obtain an injunction, without posting a bond, to prevent any breach or threatened breach of any part of these Restrictive Covenants.  

In the event that any court of competent jurisdiction finds that the limitations set forth in these Restrictive Covenants are overly broad with respect to duration, geographic scope or scope of prohibited activities, such court will have the authority to reduce the duration, area or activities of such provisions so as to be enforceable to the maximum extent compatible with applicable law, and such provisions will then be enforced as modified.  

Notice of Immunity – Defend Trade Secrets Act of 2016

    Company employees, contractors, and consultants may disclose Trade Secrets in confidence, either directly or indirectly, to a Federal, State, or local government official, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, Company employees, contractors, and consultants who file retaliation lawsuits for reporting a suspected violation of law may disclose related Trade Secrets to their attorney and use them in related court proceedings, as long as the individual files documents containing the Trade Secret under seal and does not otherwise disclose the Trade Secret except pursuant to court order.
Definitions for Purposes of this Agreement
    “Business” means areas of actual or demonstrably anticipated research and development conducted (or to be conducted) by, or for the benefit of, Company as well as all products or services sold by, on behalf of, or for the benefit of Company worldwide. 
    “Competitive Business” means any domestic or international business or firm (including any business in the process of being formed or planned) that is engaged, or has active plans to become engaged, in any line of business of the Company with which you have had direct functional accountability, or for which you provided leadership or support, during your last eighteen (18) months of employment with the Company.  
    “Confidential Information” includes, but is not limited to strategic plans, trade secrets, inventions, discoveries, technical and operating know-how, accounting information, product information, marketing and sales data, business strategies, customer information, and employee data of the Company that is proprietary in nature, and any similar information, data or materials of third parties that the Company has a duty to keep confidential
    “Developments” means all discoveries, inventions, innovations, improvements, computer programs and related documentation, and other works of authorship, mask works, designs, know-how, ideas and information made, written, conceived and/or reduced to practice, in whole or in part, (whether or not patentable or subject to other forms of protection) by Employee, individually or with any other person, during and after the period of Employee’s employment by Company that: (a) relate in any manner to the Business or activities of Company; and/or (b) are created: (i) at any time using Company resources, including, but not limited to, Company 

computers, cellphones, smartphones, etc.; (ii) during working hours; (iii) at a Company facility; (iv) by, or on behalf of, Company; and/or (v) using Confidential Information. 
    “Employee Statutorily Exempt Developments” means any Developments which qualify fully under the provisions of any applicable statute (including, e.g., Section 2870 of the California Labor Code) that prohibits the assignment to Company of Employee’s rights in any inventions developed entirely on Employee’s own time without using the Company’s equipment, supplies, facilities, resources, trade secrets or Confidential Information (i.e., excluding inventions that either (i) relate at the time of conception or reduction to practice of the invention to the Company’s Business, or actual or demonstrably anticipated research or development; or (ii) result from any work performed by Employee for the Company).
    “Intellectual Property” means any intellectual and industrial property and all rights thereof, including, but not limited to, patents, utility models, semi-conductor topography rights; copyrights, mask works, authors’ rights, registered and unregistered trademarks, brands, domain names, trade secrets, know-how and other rights in information, drawings, logos, plans, database rights, technical notes, prototypes, processes, methods, algorithms, any technical-related documentation, any software, registered designs and other designs, in each case, whether registered or unregistered and including applications for registration, and all rights or forms of protection having equivalent or similar effect anywhere in the world.
Governing Law; Jurisdiction

This Agreement will be governed and interpreted in accordance with the laws of the State of Delaware without reference to its choice of law principles.  Any action arising out of or related to this Agreement will be brought in the state or Federal courts located in Delaware, and you and the Company consent to the jurisdiction and venue of such courts.  

Amendment; Waiver

No provision of this Agreement may be modified, waived, or discharged unless such waiver, modification or discharge is in writing.  Any failure by you or the Company to enforce any of the provisions of this Agreement should not be construed to be a waiver of such provisions or any right to enforce each and every provision in the future.  A waiver of any breach of this Agreement will not be construed as a waiver of any other or subsequent breach.

Successors; Binding Agreement

Upon the legal separation of Arconic Corporation from Arconic Inc. (such separation, the “Spinoff”), this Agreement will be assigned to Arconic Corporation and, from and after the Spinoff, all references herein to “Arconic” shall be deemed to refer to Arconic Corporation and all references herein to the “Company” shall be deemed to refer to Arconic Corporation collectively with its subsidiaries, unless the context clearly indicates otherwise.

The Company has the right to assign its rights and obligations under this Agreement to any entity that acquires all or substantially all of the assets of the business for which you work, and continues your employment.  The rights and obligations of the Company under this Agreement will inure to the benefit and be binding upon the successors and assigns of the Company

Severability

In the event that any one or more of the provisions of this Agreement is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remainder of this Agreement will not in any way be affected or impaired thereby.

This Agreement is the entire agreement between the parties with respect to the matters covered by this Agreement and it replaces all previous agreements, oral or written, between the parties regarding such matters.  PROVISIONS OF THIS AGREEMENT MAY NOT BE WAIVED OR CHANGED EXCEPT BY A SUBSEQUENT AGREEMENT SIGNED BY YOU AND AN OFFICER OF THE COMPANY.

If you agree to the terms of this Agreement, please sign on the line provided below and return two signed copies.  A fully executed copy will be returned to you for your files after it is signed by the Company.  

ARCONIC INC.

By: /s/ Melissa M. Miller        

AGREED TO AND ACCEPTED AS OF THIS 6TH DAY OF FEBRUARY, 2020:

/s/ Diana C. Toman            
Diana Toman

EXHIBIT B

GENERAL RELEASE FOLLOWING SEPARATION

In exchange for the payments, benefits and other consideration provided by Arconic Corporation and each of its parents, subsidiaries and affiliates (“Arconic” or the “Company”) as set forth in the Separation Agreement and Release dated November 17, 2021 (the “November 17, 2021 Agreement”), which Diana Toman (“you” or “Employee”) acknowledges and agrees are just and sufficient consideration for the waivers, releases and commitments set forth herein, Employee hereby IRREVOCABLY AND UNCONDITIONALLY agrees to WAIVE, RELEASE AND FOREVER DISCHARGE the Company and the Company Releasees (as defined in Paragraph 3 of the November 17, 2021 Agreement) from any and all claims, grievances, injuries, controversies, agreements, covenants, promises, debts, accounts, actions, causes of action, suits, arbitrations, sums of money, wages, attorneys’ fees, costs and/or damages capable of being waived by law, or any right to any monetary recovery or any other personal relief, whether known or unknown, in law or in equity, by contract, tort, law of trust or pursuant to federal, state or local statute, regulation, ordinance or common law, which Employee may now have, ever has had, or may hereafter have, based upon, arising from, or relating to any fact or set of facts, whether known or unknown to Employee, at any time prior to and until the date of execution of this Exhibit B, including but not limited to, claims arising out of or relating in any way to Employee’s employment relationship with the Company or other associations with the Company or the Company Releasees or any termination thereof.  

Without limiting the generality of the foregoing, this waiver, release, and discharge includes any claim or right based upon or arising under any federal, state or local fair employment practices and equal opportunity laws, including, but not limited to, Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §§ 2000e, et seq. (“Title VII”); the Equal Pay Act of 1963, 29 U.S.C. § 206(d) (the “Equal Pay Act” or “EPA”); the Americans with Disabilities Act, 29 U.S.C. § 12101 et seq. (“ADA”); the Employee Retirement Income Security Act of 1974, 29 U.S.C. §§ 1001, et seq. (“ERISA”) (except for vested benefits otherwise entitled); the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq. (“ADEA”); the Older Workers’ Benefits Protection Act (“OWBPA”); the Family and Medical Leave Act of 1993, including all amendments thereto; the Pennsylvania Human Relations Act, including age and sexual harassment claims; the Pennsylvania Equal Pay Law; the Pennsylvania Whistleblower Law; the Pennsylvania Pregnancy Guidelines of the Pennsylvania Human Relations Commission; Kansas Act Against Discrimination, including age and sexual harassment claims; Kansas Equal Pay Law; Kansas Age Discrimination in Employment Act; Kansas Discrimination Against Military Personnel Act; Kansas Discrimination Against Victims of Domestic Violence or Sexual Assault Act; Kansas’ whistleblower protection laws (including Kan. Stat. Ann. §§ 39-1403, 39-1432, 44-615 & 44-636); Kansas Minimum Wage and Maximum Hours Law; Kansas WARN Act; any federal, state, local, and/or municipal statute, law, amendment, directive, order, and/or regulation enacted in response to the COVID-19 pandemic; and any other federal, state, or local statutes, common law, or regulation, including any and all amendments to the foregoing, provided that nothing herein constitutes a release or waiver of any claim or right that may arise after the execution of this Exhibit B.

Employee understands and acknowledges that Employee has received all amounts due from the Company relating to Employee’s employment with the Company, including but not limited to, compensation, equity, options, shares of stock, phantom stock, wages, commissions, bonuses, sick pay, personal leave pay, severance pay, vacation pay, or other compensation, benefits, or payments of any kind or nature, and that no other amounts are due to Employee other than as set forth in the November 17, 2021 Agreement and all exhibits thereto.  

Notwithstanding the generality of the foregoing, nothing herein constitutes a release or waiver by you of, or prevents you  from making or asserting:  (i) any claim or right you may have under COBRA; (ii) any claim or right you may have for unemployment insurance or workers’ compensation benefits; (iii) any claim to vested benefits under the written terms of a qualified employee pension benefit plan; (iv) any medical claim incurred during your employment that is payable under applicable medical plans or an employer-insured liability plan; (v) any claim or right that may arise after the execution of this Agreement; (vi) any claim or right you may have under this Agreement; (vii) any claim to indemnification under your Indemnification Agreement with the Company; (viii) any claim that is not otherwise waivable under applicable law or (ix) any claim that you may have as a shareholder or equity owner of the Company.  In addition, nothing herein shall prevent you from filing a charge or complaint with the Equal Employment Opportunity Commission (“EEOC”) or similar federal or state agency or your ability to participate in any investigation or proceeding conducted by such agency; provided, however, that you are waiving any right to recover monetary damages or any other form of personal relief in connection with any such charge, complaint, investigation, or proceeding.  To the extent you receive any personal or monetary relief in connection with any such EEOC charge, complaint, investigation, or proceeding, the Company will be entitled to an offset for the consideration made pursuant to Paragraph 2 of the November 17, 2021 Agreement.  

By signing this Exhibit B, Employee understands and acknowledges that Employee was advised of and afforded the opportunity to take advantage of each of the protections set forth in Paragraph 17 of the November 17, 2021 Agreement, including, but not limited to: (i) consultation with an attorney before signing this Exhibit B; (ii) at least twenty-one (21) calendar days in which to consider Exhibit B; and (iii) at least seven (7) calendar days in which to revoke Exhibit B after signature.  Employee further acknowledges that Employee freely, voluntarily, and knowingly entered into this Exhibit B after due consideration.

This Exhibit B incorporates by reference, as if set forth fully herein, all terms and conditions of the November 17, 2021 Agreement between the Company and Employee, including the recitation of consideration provided by the Company.  By signing this Exhibit B, Employee waives, releases, and forever discharges any and all claims that may have arisen through the date of Employee’s execution of this Exhibit B.  It is not Employee’s intention to otherwise change, alter or amend any of the terms and conditions of the November 17, 2021 Agreement, for which Employee received adequate consideration, and which Agreement remains in full force and effect.  Employee acknowledges and agrees that Employee continues to be bound by the terms and conditions of the November 17, 2021 Agreement.

This Exhibit B shall become effective upon the expiration of the seven (7) day revocation period described above, provided Employee has not exercised Employee’s right to revoke.  

I UNDERSTAND AND ACKNOWLEDGE THAT I SHALL EXECUTE THIS EXHIBIT B ON, BUT NOT BEFORE, MY SEPARATION DATE WITH THE COMPANY.

            UNDERSTOOD, AGREED TO
                    AND ACCEPTED WITH THE
                    INTENTION TO BE LEGALLY BOUND:

                    __________________________________
                    Diana Toman

                    Date: ___________________________EX-4.2

 Exhibit 4.2 
  

 
 THERMO FISHER SCIENTIFIC (FINANCE I)
B.V., 
 as Issuer 
 THERMO
FISHER SCIENTIFIC INC., 
 as Guarantor 

AND 
 THE BANK OF NEW YORK MELLON
TRUST COMPANY, N.A. 
 as Trustee 

FOURTH SUPPLEMENTAL INDENTURE 

Dated as of November 18, 2021 

Floating Rate Senior Notes due 2023 

0.000% Senior Notes due 2023 

0.000% Senior Notes due 2025 
  

 

 THIS FOURTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) is dated as of
November 18, 2021 among THERMO FISHER SCIENTIFIC (FINANCE I) B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, with its corporate seat
(statutaire zetel) in Breda, the Netherlands, and its registered office at Takkebijsters 1, 4817 BL Breda, the Netherlands, registered with the Dutch Trade Register of the Chamber of Commerce under number 66428319 (the
“Company”), THERMO FISHER SCIENTIFIC INC., a Delaware corporation (the “Guarantor”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as trustee (the “Trustee”).

 RECITALS 
 WHEREAS, the
Company, the Guarantor and the Trustee executed and delivered an indenture, dated as of August 9, 2016 (the “Base Indenture” and, as supplemented by this Supplemental Indenture, the “Indenture”), to provide for
the issuance by the Company from time to time of debt securities evidencing the Company’s unsecured indebtedness fully and unconditionally guaranteed by the Guarantor. 

WHEREAS, the Company has authorized the issuance of €1,700,000,000 aggregate principal amount of Floating Rate Senior Notes due 2023 (the
“Floating Rate Notes”), €550,000,000 aggregate principal amount of the Company’s 0.000% Senior Notes due 2023 (the “2023 Notes”) and €550,000,000 aggregate principal amount of the
Company’s 0.000% Senior Notes due 2025 (the “2025 Notes” and, together with the 2023 Notes, the “Fixed Rate Notes,” and the Fixed Rate Notes, together with the Floating Rate Notes, the
“Notes”). 
 WHEREAS, the Company and the Guarantor desire to enter into this Supplemental Indenture pursuant to
Section 9.01 of the Base Indenture to establish the form and terms of the Notes in accordance with Sections 2.01 and 2.02 of the Base Indenture. 

WHEREAS, the Guarantor desires to guarantee the Notes on the terms set forth in Article XIV of the Base Indenture. 

WHEREAS, the entry into this Supplemental Indenture by the parties hereto is in all respects authorized by the provisions of the Base
Indenture. 
 WHEREAS, all things necessary to make this Supplemental Indenture a valid and legally binding agreement according to its terms
have been done. 
 NOW, THEREFORE, for and in consideration of the foregoing premises and for other good and valuable consideration, the
Company, the Guarantor and the Trustee, mutually covenant and agree for the equal and proportionate benefit of the respective Holders from time to time of the Notes as follows: 

  
 2 

 ARTICLE I 

Section 1.1 Defined Terms. 

(1) Capitalized terms used but not defined in this Supplemental Indenture shall have the meanings ascribed thereto in the Base Indenture. 

(2) A term defined anywhere in this Supplemental Indenture has the same meaning throughout. 

(3) The singular includes the plural and vice versa. 

(4) Headings are for convenience of reference only and do not affect the interpretation. 

(5) As used herein, the following defined terms shall have the following meanings with respect to the Notes and this Supplemental Indenture
only: 
 “Below Investment Grade Rating Event” means, with respect to a series of Notes, such Notes are downgraded below
Investment Grade Rating by any two of the Rating Agencies on any date during the period (the “Trigger Period”) commencing 60 days prior to the first public announcement by the Company or the Guarantor of the occurrence of a
Change of Control (or pending Change of Control) and ending 60 days following consummation of such Change of Control (which Trigger Period shall be extended so long as the rating of such Notes is under publicly announced consideration for
possible downgrade by at least two of such Rating Agencies on such 60th day, such extension to last with respect to each such Rating Agency until the date on which such Rating Agency considering such possible downgrade either (x) rates
such Notes below Investment Grade or (y) publicly announces that it is no longer considering such Notes for possible downgrade, provided that no such extension will occur if on such 60th day such Notes are rated Investment Grade by
at least two of such Rating Agencies in question and are not subject to review for possible downgrade by such Rating Agencies). The Trustee shall not be responsible for monitoring, or charged with knowledge of, the ratings of the Notes. 

“Business Day” means any day, other than a Saturday or Sunday, (1) which is not a day on which banking institutions in
The City of New York or London are authorized or required by law, regulation or executive order to close and (2) on which the Trans-European Automated Real-Time Gross Settlement Express Transfer system (the TARGET2 system), or any successor
thereto, is open. 
 “Calculation Agency Agreement” means the Calculation Agency Agreement, dated as of November 18,
2021, between the Company and the Calculation Agent. 
 “Calculation Agent” means The Bank of New York Mellon, London
Branch, or any successor. 
 “Change of Control” means the occurrence of any of the following: (1) the direct or
indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Guarantor and its subsidiaries taken
as a whole to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Guarantor or one of its direct or indirect wholly-owned subsidiaries; (2) the consummation of any transaction (including,
without limitation, any merger or consolidation) as a result of which any “person” (as that term is 

  
 3 

 
used in Section 13(d)(3) of the Exchange Act) becomes the “beneficial owner” (as defined in Rules 13d-3 and
13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the Guarantor’s outstanding Voting Stock or other Voting Stock into which the Guarantor’s Voting Stock is reclassified,
consolidated, exchanged or changed, measured by voting power rather than number of shares; (3) the Guarantor consolidates with, or merges with or into, any “person” or “group” (as that term is used in Section 13(d)(3)
of the Exchange Act), or any “person” or “group” consolidates with, or merges with or into, the Guarantor, in any such event pursuant to a transaction in which any of the Guarantor’s Voting Stock or the Voting Stock of such
other person is converted into or exchanged for cash, securities or other property, other than any such transaction where the shares of the Guarantor’s Voting Stock outstanding immediately prior to such transaction constitute, or are converted
into or exchanged for, a majority of the Voting Stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction; or (4) the adoption of a plan relating to the
Guarantor’s liquidation or dissolution. Notwithstanding the foregoing, a transaction will not be deemed to involve a Change of Control if (a) the Guarantor becomes a direct or indirect wholly-owned subsidiary of a holding company (which
shall include a parent company) and (b)(i) the holders of the Voting Stock of such holding company immediately following that transaction are substantially the same as the holders of the Guarantor’s Voting Stock immediately prior to that
transaction or (ii) no “person” (as that term is used in Section 13(d)(3) of the Exchange Act) (other than a holding company satisfying the requirements of this sentence) becomes the “beneficial owner” (as defined in
Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the voting power of the Voting Stock of such holding company immediately
following such transaction. 
 “Change of Control Triggering Event” means, with respect to any series of Notes, the
occurrence of both a Change of Control and a Below Investment Grade Rating Event. 
 “Clearing System Business Day” means
Monday to Friday, except December 25 and January 1. 
 “Clearstream” means Clearstream Banking S.A. 

“Common Safekeeper” means, with respect to the Global Notes, Euroclear, or such successor as Euroclear shall designate. 

“Common Service Provider” or “CSP” means, with respect to the Global Notes, The Bank of New York Mellon,
London Branch, which is the entity appointed by the ICSDs to service the Notes, or such successor as the ICSDs shall designate. 

“Comparable Bond Rate” means, for any Optional Redemption Date, the rate per annum equal to the annual equivalent yield to
maturity or interpolated yield to maturity (on a day count basis), computed as of the third Business Day immediately preceding that Optional Redemption Date, of the Comparable Government Issue, assuming a price for the Comparable Government Issue
(expressed as a percentage of its principal amount) equal to the Comparable Price for that Optional Redemption Date. 

  
 4 

 “Comparable Government Issue” means, with respect to either series of Fixed
Rate Notes to be redeemed, the euro-denominated security issued by the German government selected by an Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term of such series of Fixed Rate Notes to
be redeemed (assuming, with respect to the 2025 Notes, that such 2025 Notes to be redeemed matured on the Par Call Date) that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of
corporate debt securities of comparable maturity to the remaining term of such series of Fixed Rate Notes to be redeemed. 

“Comparable Price” means, with respect to any Optional Redemption Date, (a) the average of the Reference Dealer
Quotations for such Optional Redemption Date, after excluding the highest and lowest of the Reference Dealer Quotations, (b) if the Company obtains fewer than four Reference Dealer Quotations, the arithmetic average of those quotations or
(c) if the Company obtains only one Reference Dealer Quotation, such Reference Dealer Quotation. 
 “Electronic Means”
shall mean the following communications methods: e-mail, facsimile transmission, secure electronic transmission containing applicable authorization codes, passwords and/or authentication keys issued by the
Trustee, or another method or system specified by the Trustee as available for use in connection with its services hereunder. 

“Euroclear” means Euroclear Bank S.A./N.V. 

“euro” or “€” means the single currency introduced at the third stage of the European Economic and
Monetary Union pursuant to the Treaty establishing the European Community, as amended. 
 “Fitch” means Fitch Ratings,
Limited, and any successor to its rating agency business. 
 “Global Note” means with respect to each series of Notes,
the permanent, registered security in global form which will represent the relevant series of Notes on issue and includes any Global Note intended to be held under the new Safekeeping Structure and registered in the name of a nominee for the Common
Safekeeper. 
 “ICMA” means the International Capital Markets Association. 

“ICSD(s)” means Clearstream and/or Euroclear, as the case may be and/or any additional or alternative clearing system
approved by Parent, the Company, the Trustee and the Paying Agent (provided that such additional or alternative clearing system must also be authorized to hold a Global Note as eligible collateral for Eurosystem monetary policy and intra-day credit operations) collectively. 
 “Independent Investment Banker” means one
of the Reference Dealers appointed by the Company to act as the Independent Investment Banker. 
 “Internal Revenue
Code” means the U.S. Internal Revenue Code of 1986, as amended. 

  
 5 

 “Investment Grade Rating” means a rating by Moody’s equal to or higher
than Baa3 (or the equivalent under a successor rating category of Moody’s) or a rating by S&P equal to or higher than BBB- (or the equivalent under any successor rating category of S&P) or a
rating by Fitch equal to or higher than BBB- (or the equivalent under any successor rating category of Fitch). 

“Moody’s” means Moody’s Investors Service, Inc., and any successor to its rating agency business. 

“New Safekeeping Structure” or “NSS” means a structure where a Global Note is registered in the name of a
Common Safekeeper (or its nominee) and will be deposited on or about the issue date with the Common Safekeeper. 
 “Optional
Redemption Date” when used with respect to any Note to be redeemed at the Company’s option, means the date fixed for such redemption by or pursuant to Section 1.4A of this Supplemental Indenture. 

“Optional Redemption Price” when used with respect to any Note to be redeemed at the Company’s option, means the price
at which it is to be redeemed pursuant to Section 1.4A of this Supplemental Indenture. 
 “Par Call Date” means
October 18, 2025. 
 “Paying Agency Agreement” means the Paying Agency Agreement, dated as of November 18, 2021
between the Company and the Paying Agent. 
 “Paying Agent” means The Bank of New York Mellon, London Branch, or any
successor. 
 “Primary Bond Dealer” means a broker or dealer of, and/or a market maker in German government
bonds. 
 “Rating Agencies” means (1) Moody’s, S&P and Fitch; and (2) if any of Moody’s, S&P or
Fitch ceases to rate the applicable series of Notes or fails to make a rating of such Notes publicly available for any reason, a “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) under the
Exchange Act, selected by the Company (as certified by a resolution of its Board of Directors) as a replacement agency for any of Moody’s, S&P or Fitch, or all of them, as the case may be. 

“Reference Dealer” means each of (i) Barclays Bank PLC, Morgan Stanley Europe SE, BofA Securities Europe SA, Citigroup
Global Markets Europe AG and Mizuho Securities Europe GmbH and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that is a Primary Bond Dealer that the Company selects
in connection with the particular redemption, and each of their respective successors, provided that if at any time any of the above is not a Primary Bond Dealer, the Company will substitute that entity with another
nationally recognized investment banking firm that the Company selects that is a Primary Bond Dealer. 

  
 6 

 “Reference Dealer Quotations” means, with respect to each Reference Dealer
and any Optional Redemption Date, the arithmetic average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Government Issue (expressed in each case as a percentage of its principal amount) quoted in
writing to the Independent Investment Banker by such Reference Dealer at 11:00 a.m., London time, on the third Business Day preceding such Optional Redemption Date. 

“Remaining Scheduled Payments” means, with respect to either series of Fixed Rate Notes to be redeemed, the remaining
scheduled payments of the principal thereof and interest thereon that would be due after the related Optional Redemption Date but for such redemption (assuming, with respect to the 2025 Notes, that such 2025 Notes to be redeemed matured on the Par
Call Date); provided, however, that, if such Optional Redemption Date is not an interest payment date with respect to such series of Fixed Rate Notes, the amount of the next succeeding scheduled interest payment thereon will be reduced
by the amount of interest accrued thereon to such Optional Redemption Date. 
 “S&P” means S&P Global Ratings, a
division of S&P Global, Inc., and any successor to its rating agency business. 
 “Specified Office of the Paying
Agent” means, initially, the London Branch of The Bank of New York Mellon, located at One Canada Square, London E14 5AL, England. 

“TARGET2 Business Day” means any day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer
System(TARGET2), or any successor system, is open for business. 
 “Treasury Regulations” means the U.S. Treasury
Regulations promulgated under the Internal Revenue Code. 
 “United States” means the United States of America, the states
of the United States, and the District of Columbia. 
 “Voting Stock” means with respect to any specified person (as that
term is used in Section 13(d)(3) of the Exchange Act) Capital Stock of any class or kind the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar
functions) of such person, even if the right to vote has been suspended by the happening of such a contingency. 

Section 1.2 Terms of the Notes. 

The following terms relate to the Notes: 

(1) The Floating Rate Notes shall constitute a separate series of Notes having the title “Floating Rate Senior Notes due
2023,” the 2023 Notes shall constitute a separate series of Notes having the title “0.000% Senior Notes due 2023” and the 2025 Notes shall constitute a separate series of Notes having the title “0.000% Senior Notes due
2025.” 

  
 7 

 (2) The aggregate principal amount of the Floating Rate Notes (the “Initial Floating
Rate Notes”), the 2023 Notes (the “Initial 2023 Notes”) and the 2025 Notes (the “Initial 2025 Notes,” and, together with the Initial Floating Rate Notes and the Initial 2023 Notes, the “Initial
Notes”) that may be initially authenticated, delivered and effectuated under the Indenture shall be €1,700,000,000, €550,000,000 and €550,000,000, respectively. The Company may from time to time, without the consent of the
Holders of any series of Notes, issue additional Floating Rate Notes (the “Additional Floating Rate Notes”), Additional 2023 Notes (the “Additional 2023 Notes”) and Additional 2025 Notes (the “Additional
2025 Notes,” and, together with the Additional Floating Rate Notes and the Additional 2023 Notes, the “Additional Notes”) having the same terms (except for the issue date, offering price and, if applicable, the first
interest payment date) as the Initial Floating Rate Notes, Initial 2023 Notes and the Initial 2025 Notes, as the case may be. Any Additional Notes of a series and the Initial Notes of such series shall constitute a single series under the Indenture;
provided that if any Additional Notes of a series are not fungible with the Initial Notes of such series for U.S. federal income tax purposes, such Additional Notes of such series shall not have the same ISIN or Common Code as the Initial
Notes of such series. All references to a series of Notes shall include both the Initial Notes and any Additional Notes of such series, unless the context otherwise requires. The aggregate principal amount of each of the Floating Rate Notes, the
2023 Notes and the 2025 Notes shall be unlimited. The entire respective outstanding principal amount of the Floating Rate Notes, the 2023 Notes and the 2025 Notes shall be payable on November 18, 2023, November 18, 2023 and
November 18, 2025, respectively. The principal of each Note payable at maturity or upon earlier redemption shall be paid against presentation and surrender of such Note at the office or agency maintained for such purposes in London, initially,
the Specified Office of the Paying Agent. In the case of a Global Note in respect of the Notes intended to be held under the New Safekeeping Structure (the “NSS”), save for the purposes of determining the Notes that are outstanding
for consent or voting purposes under the Base Indenture, the Trustee shall rely on the records of the ICSDs in relation to any determination of the principal amount outstanding of such Global Note. For this purpose “records” means the
records that each of the ICSDs holds for its customers which reflects the amount of such customer’s interest in the Notes. 
 (3) (a)
The Floating Rate Notes shall bear interest at a rate equivalent to the 3-month EURIBOR (the “Floating Rate Base Rate”) plus 0.200% per annum, as calculated by the Calculation Agent;
provided, however, that the minimum interest rate shall be zero. The Floating Rate Notes will bear interest from November 18, 2021 or from the immediately preceding Floating Rate Interest Payment Date (as defined below) to which
interest has been paid. Interest on the Floating Rate Notes shall be payable quarterly in arrears on February 18, May 18, August 18 and November 18 of each year (each, a “Floating Rate Interest Payment Date”),
commencing on February 18, 2022; provided, that, if any Floating Rate Interest Payment Date (other than any maturity date or earlier date of redemption) would be a day that is not a Business Day, such Floating Rate Interest Payment Date
shall be the next succeeding day that is a Business Day (and no additional interest will accrue or otherwise accumulate on the amount payable for the period from and after such Floating Rate Interest Payment Date); except that if such next
succeeding Business Day falls in the next succeeding calendar month, such Floating Rate Interest Payment Date shall be the immediately preceding Business Day. The interest rate on the Floating Rate Notes will be reset quarterly on February 18,
May 18, August 18 and November 18 of each year (each, an “Floating Rate Interest Reset Date”), commencing on February 18, 2022; provided, that, if any Floating Rate Interest Reset Date

  
 8 

 
would be a day that is not a Business Day, such Floating Rate Interest Reset Date shall be the next succeeding day that is a Business Day, except that if such next succeeding Business Day falls
in the next succeeding calendar month, such Floating Rate Interest Reset Date shall be the immediately preceding Business Day. The initial Floating Rate Base Rate for the Floating Rate Notes in effect from November 18, 2021 to, but excluding,
the first Floating Rate Interest Reset Date will be the 3-month EURIBOR in effect on November 16, 2021. The interest rate on the Floating Rate Notes will be determined on the second TARGET2 Business Day
preceding the applicable Floating Rate Interest Reset Date (a “EURIBOR Interest Determination Date”). Interest on a Floating Rate Interest Payment Date shall be paid to the Persons in whose names the Floating Rate Notes are
registered on the Security Register at the close of business on the regular record date. The regular record date for the Floating Rate Notes shall be the Clearing System Business Day immediately preceding each Interest Payment Date. Interest on the
Floating Rate Notes will be computed on the basis of a 360-day year and the actual number of days in the period for which interest is being calculated. 

(b) The Floating Rate Base Rate that takes effect on any Floating Rate Interest Reset Date shall be equal to the interest rate for deposits in
euro designated as “EURIBOR” and sponsored jointly by the European Banking Federation and ACI — the Financial Market Association (or any company established by the joint sponsors for purposes of compiling and publishing that rate) on
each EURIBOR Interest Determination Date, and will be determined by the Calculation Agent in accordance with the following provisions: 
  

	 	(i)	 EURIBOR will be the offered rate for deposits in euro having a maturity of three months, as that rate appears
on Reuters Page EURIBOR01 as of 11:00 A.M., Brussels time, on the relevant EURIBOR Interest Determination Date. 

  

	 	(ii)	 If the rate described in clause (i) above does not appear on Reuters Page EURIBOR01, EURIBOR will be
determined on the basis of the rates, at approximately 11:00 A.M., Brussels time, on the relevant EURIBOR Interest Determination Date, at which deposits of the following kind are offered to prime banks in the Euro-Zone interbank market by the
principal Euro-Zone office of each of four major banks in that market selected by the Company: euro deposits having a maturity of three months beginning on such Interest Reset Date and in a principal amount of not less than €1,000,000 that is
representative for a single transaction in such market at such time. The Company will request the principal Euro-Zone office of each of these banks to provide to the Paying Agent and Calculation Agent a quotation in writing of its rate. If at least
two quotations are provided in writing, EURIBOR for such EURIBOR Interest Determination Date will be the arithmetic mean (rounded upwards in accordance with Section 1.2(3)(d) hereof) of such quotations, calculated by the Calculation Agent. The
Company will ensure that the Calculation Agent is provided with appropriate contact details of the relevant personnel at each of the reference banks that the Calculation Agent will be requested to contact to provide such quotation of its rates.

  
 9 

	 	(iii)	 If fewer than two quotations are provided as described in clause (ii) above, EURIBOR for the relevant
EURIBOR Interest Determination Date will be the arithmetic mean of the rates for loans of the following kind to leading Euro-Zone banks quoted in writing, at approximately 11:00 A.M., Brussels time, on such EURIBOR Interest Determination Date, by
three major banks in the Euro-Zone selected by the Company: loans of euro having a maturity of three months beginning on such Floating Rate Interest Reset Date and in a principal amount of not less than €1,000,000 that is representative for a
single transaction in such market at such time. 

  

	 	(iv)	 If fewer than three banks selected by the Company are quoting as described in clause (iii) above, EURIBOR
shall be the EURIBOR then in effect on such EURIBOR Interest Determination Date. 

 Notwithstanding the foregoing, if the Company, in its
sole discretion, determines that EURIBOR has been permanently discontinued, or the reference to EURIBOR becomes illegal or most other debt obligations similar to the Floating Rate Notes have converted away from EURIBOR to a new reference rate, the
Calculation Agent shall use, as directed in writing by the Company, as a substitute for EURIBOR for each future interest determination date, the alternative reference rate (the “Alternative Rate”) selected by a central bank, reserve
bank, monetary authority or any similar institution (including any committee or working group thereof) that is consistent with accepted market practice regarding a substitute for EURIBOR. As part of such substitution, the calculation agent will, as
directed in writing by the Company, make such adjustments (the “Adjustments”) to the Alternative Rate and/or the spread thereon, as well as the business day convention, interest determination dates and related provisions and
definitions, in each case that are consistent with accepted market practice for the use of such Alternative Rate for debt obligations such as the Floating Rate Notes. If the Company determines there is no clear market consensus as to whether any
rate has replaced EURIBOR in customary market usage, the Company may appoint an independent financial advisor (the “IFA”) to determine an appropriate Alternative Rate, and any Adjustments, and the decision of the IFA shall be
binding on the Company, the Calculation Agent, the Trustee and the Holders. If, however, the Company determines that EURIBOR has been discontinued, but for any reason an Alternative Rate has not been determined, the rate of EURIBOR for the next
interest period shall be equal to such rate on the interest determination date when EURIBOR was last available on Reuters Page EURIBOR 01, as determined by the Calculation Agent. 

(c) Upon the request of any Holder to the Calculation Agent, the Calculation Agent will provide the interest rate then in effect on the
Floating Rate Notes and, if determined, the interest rate that will become effective on the next Floating Rate Interest Reset Date. 
 (d)
All percentages resulting from any calculation with respect to the Floating Rate Notes will be rounded upward or downward, as appropriate, to the next higher or lower one hundred-thousandth of a percentage point (e.g., 9.876541% (or .09876541)
being rounded down to 9.87654% (or .0987654) and 9.876545% (or .09876545) being rounded up to 9.87655% (or .0987655)). All amounts used in or resulting from any calculation with respect to the Floating Rate Notes will be rounded upward or downward,
as appropriate, to the nearest cent, in the case of euro amounts or U.S. dollars, or to the nearest corresponding hundredth of a unit, in the case of a currency other than euro amounts or U.S. dollars, with
one-half cent or one-half of a corresponding hundredth of a unit or more being rounded upward. 

  
 10 

 (e) In no event shall the Calculation Agent be responsible for determining the Alternative
Rate or any substitute for EURIBOR, or for making any Adjustments to any alternative benchmark or spread thereon, the business day convention, interest determination dates or any other relevant methodology for calculating any such substitute or
successor benchmark. In connection with the foregoing, the Calculation Agent will be entitled to conclusively rely on any determinations made by the Company and will have no liability for such actions taken at the direction of the Company. 

(4) The rate at which the 2023 Notes shall bear interest shall be 0.000% per annum and the rate at which the 2025 Notes shall bear interest
shall be 0.000% per annum. The date from which interest shall accrue on each series of Fixed Rate Notes shall be the most recent Interest Payment Date to which interest has been paid or provided for or, if no interest has been paid, from
November 18, 2021. The Interest Payment Dates for the Fixed Rate Notes shall be November 18 of each year, beginning on November 18, 2022; provided that if any Interest Payment Date for either series of Fixed Rate Notes falls on a day
that is not a Business Day, the required payment shall be made on the next Business Day as if it were made on the date the payment to Holders was due and no interest shall accrue on the amount so payable for the period from and after that Interest
Payment Date. The regular record date for the Fixed Rate Notes shall be the Clearing System Business Day immediately preceding each Interest Payment Date. Interest on the Fixed Rate Notes shall be computed on the basis of an ACTUAL/ACTUAL (ICMA) (as
defined in the rulebook of ICMA) day count convention. 
 (5) The Notes shall be issuable in whole in the form of Global Notes, registered in
the name of the nominee of Euroclear as Common Safekeeper and deposited with, or on behalf of, the Common Safekeeper for credit by the Common Safekeeper to the respective accounts of beneficial owners represented thereby (or such other accounts as
they may direct). The Floating Rate Notes shall be substantially in the form attached hereto as Exhibit A and each Fixed Rate Note shall be substantially in the form attached hereto as Exhibit B, the terms of which are herein incorporated by
reference. The Notes shall be issuable in denominations of €100,000 or any integral multiple of €1,000 in excess thereof. 
 (6)
The Fixed Rate Notes may be redeemed at the option of the Company prior to the maturity date, as provided in Section 1.4A and 1.4B hereof. 

(7) The Notes shall not have the benefit of any sinking fund. 

(8) Except as provided herein, the Holders shall have no special rights in addition to those provided in the Base Indenture upon the occurrence
of any particular events. 
 (9) The Notes shall be general unsecured and unsubordinated obligations of the Company and shall be ranked
equally among themselves. 
 (10) The Notes are not convertible into shares of common stock or other securities of the Company. 

  
 11 

 (11) The covenants set forth in Section 1.5 hereof shall be applicable to the Notes.

 (12) The transfer and exchange provisions set forth in Section 2.05 of the Base Indenture shall be applicable to the Notes. 

(13) All payments of principal of, and interest (including Additional Amounts, if any) and premium (if any) on, the Notes shall be payable in
euro; provided, however, that if, on or after November 9, 2021, euro is unavailable to the Company or, in the case of the Guarantee, the Guarantor due to the imposition of exchange controls or other circumstances beyond the
Company’s or the Guarantor’s control or if the euro is no longer being used by the then member states of the European Economic and Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public
institutions of or within the international banking community, then all payments in respect of the Notes shall be made in U.S. dollars until the euro is again available to the Company or, in the case of the Guarantee, the Guarantor or so used.
In such circumstances, the amount payable on any date in euro shall be converted by the Company into U.S. dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second Business Day prior to the
relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent U.S. dollar/euro exchange rate published in The Wall Street Journal on or prior to the
second Business Day prior to the relevant payment date. Any payment in respect of the Notes so made in U.S. dollars shall not constitute an Event of Default under the Notes or the Indenture. None of the Trustee, the Paying Agent or the
Calculation Agent shall have any responsibility for any calculation or conversion in connection with the foregoing. Any references elsewhere in the Indenture or the Notes to payments being made in euro notwithstanding, payments shall be made in
U.S. dollars to the extent set forth in this Section 1.2(13). 
 (14) The Bank of New York Mellon, London Branch, shall initially
act as the Paying Agent and the Calculation Agent in accordance with the terms of the Paying Agency Agreement and the Calculation Agency Agreement, respectively. The Company hereby initially designates the Specified Office of the Paying Agent as the
office to be maintained by it where Notes may be presented for payment, registration of transfer or exchange, and where notices to or demands upon the Company in respect of the Notes or the Indenture may be served. The Security Registrar for the
Notes shall initially be the Trustee. Upon notice to the Trustee, the Company may at any time vary or terminate the appointment of any Paying Agent, Security Registrar or Calculation Agent, appoint additional or other Paying Agents, Security
Registrars or Calculation Agents and approve any change in the office through which any Paying Agent, Security Registrar or Calculation Agent acts. The Company, the Guarantor or any of the Guarantor’s Subsidiaries may act in any such capacity.

 (15) In order to provide for all payments due on the Notes as the same shall become due, the Company shall cause to be paid to the Paying
Agent, no later than 10:00 a.m. London time on the Business Day prior to the payment date of each Note, at such bank as the Paying Agent shall previously have notified the Company, in immediately available funds sufficient to meet all payments
due on such Notes. 

  
 12 

 (16) Notwithstanding any other provision of this Supplemental Indenture, the Trustee and
Paying Agent shall be entitled to make a deduction or withholding from any payment which it makes under this Supplemental Indenture for or on account of any present or future taxes, duties or charges if and to the extent so required by any
applicable law and any current or future regulations or agreements thereunder or official interpretations thereof or any law implementing an intergovernmental approach thereto or by virtue of the relevant Holder failing to satisfy any certification
or other requirements in respect of the Notes, in which event the Trustee or Paying Agent shall make such payment after such withholding or deduction has been made and shall account to the relevant authorities for the amount so withheld or deducted
and shall have no obligation to gross up any payment hereunder or pay any additional amount as a result of such withholding tax. 
 (17) The
Notes shall have the benefit of a Guarantee from the Guarantor on the terms set forth in Article XIV of the Base Indenture. 

Section 1.3 Payment of Additional Amounts. 

The provisions of Section 15.02 of the Base Indenture shall apply to the Notes. Whenever in the Notes there is mentioned, in any context,
the payment of the principal of or interest or any other amounts on, or in respect of, such Notes, such mention shall be deemed to include mention of the payment of Additional Amounts to the extent that, in such context, Additional Amounts are, were
or would be payable in respect thereof pursuant to the terms hereof and the Base Indenture, and express mention of the payment of Additional Amounts in any provision of the Notes shall not be construed as excluding the payment of Additional Amounts
in those provisions thereof where such express mention is not made. Additional Amounts will not be payable by the Company with respect to a payment made to a Holder of Securities where such Holder is subject to taxation on such payment by a relevant
taxing jurisdiction for or on account of any withholding or deduction required to be made from payments in respect of debt securities pursuant to the Dutch Withholding Tax Act 2021 (Wet bronbelasting 2021). 

Section 1.4A Optional Redemption. 

(1) The provisions of Article III of the Base Indenture, as supplemented and amended by the provisions of this Supplemental Indenture, shall
apply to the Fixed Rate Notes with respect to this Section 1.4A. 
 (2) Prior to the Par Call Date, in the case of the 2025 Notes, and
at any time, in the case of the 2023 Notes, the Fixed Rate Notes of either series shall be redeemable, in whole at any time or in part from time to time, at the Company’s option. Upon redemption of the Fixed Rate Notes of either series, the
Company shall pay an Optional Redemption Price equal to the greater of: 
  

	 	(i)	 100% of the principal amount of the Fixed Rate Notes to be redeemed, and 

 

	 	(ii)	 the sum of the present values of the Remaining Scheduled Payments of the Fixed Rate Notes to be redeemed,
discounted to the Optional Redemption Date on an annual basis (ACTUAL/ACTUAL (ICMA)) using a discount rate equal to the Comparable Bond Rate, plus, in each case, 10 basis points; 

  
 13 

 plus, in addition to such Optional Redemption Price, accrued and unpaid interest on the Fixed Rate
Notes being redeemed, if any, to, but excluding, the Optional Redemption Date. 
 In addition, on and after the Par Call Date, the 2025
Notes shall be redeemable, in whole at any time or in part from time to time, at the Company’s option, at an Optional Redemption Price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest, if
any, to, but excluding, the Optional Redemption Date. 
 (3) Notwithstanding the foregoing, installments of interest whose Stated Maturity
is on or prior to the Optional Redemption Date shall be payable on the applicable Interest Payment Date to the Holders of such Fixed Rate Notes registered as such at the close of business on the applicable regular record date pursuant to the Fixed
Rate Notes and the Indenture. 
 (4) On and after the applicable Optional Redemption Date for either series of Fixed Rate Notes, interest
shall cease to accrue on the Notes to be redeemed or any portion thereof called for redemption, unless the Company defaults in the payment of the Optional Redemption Price and accrued and unpaid interest and Additional Amounts, if any. No later than
10:00 a.m. London time on the Business Day prior to the Optional Redemption Date for any Notes to be redeemed, the Company shall deposit with the Trustee or Paying Agent, funds sufficient to pay the Optional Redemption Price of such Notes on the
Optional Redemption Date, and (except if the date fixed for redemption shall be an Interest Payment Date) accrued and unpaid interest and Additional Amounts, if any. If less than all of the Fixed Rate Notes of either series are to be redeemed, the
Notes to be redeemed shall be selected, in the case of global securities, in accordance with applicable Common Safekeeper procedures and, in the case of definitive securities, in a manner the trustee deems fair and appropriate, unless otherwise
required by law or applicable stock exchange requirements; provided that if such Notes are represented by a Global Note intended to be held under the New Safekeeping Structure, beneficial interests in such Notes will be selected for redemption by
the ICSDs in accordance with their respective standard procedures therefor; provided, however, that no such Notes of a principal amount of €100,000 or less shall be redeemed in part. The Security Registrar shall record such redemption in the
Security Register and shall provide the details of such redemption to the Common Safekeeper. The Trustee shall cause the Common Service Provider to instruct the Common Safekeeper to make such appropriate entries in their records in respect of all
such Notes redeemed by the Company to reflect such redemption. 
 (5) Notice of any optional redemption shall be transmitted at least 10
days but not more than 60 days before the applicable Optional Redemption Date to each Holder of the Notes to be redeemed; provided, however, that the Company shall notify the Trustee of the Optional Redemption Date at least 15 days prior to the date
of the giving of such notice (unless a shorter notice shall be satisfactory to the Trustee). Such notice shall be provided in accordance with Section 3.02 of the Base Indenture. A notice of redemption may, at the discretion of the Company, be
subject to one or more conditions precedent, including, but not limited to, completion of an equity offering, a financing, or other corporate transaction, provided that if such redemption or notice is subject to satisfaction of one or more
conditions precedent, such 

  
 14 

 
notice shall state that, in the Company’s discretion, the Optional Redemption Date may be postponed until up to 60 days following the notice of redemption, and such notice may be rescinded
in the event that any or all such conditions shall not have been satisfied by the Optional Redemption Date (including as it may be postponed). If the Optional Redemption Price cannot be determined at the time such notice is to be given, the actual
Optional Redemption Price applicable to the Notes that are being redeemed, calculated as described above in clause (2), shall be set forth in an Officers’ Certificate of the Company delivered to the Trustee no later than two (2) Business
Days prior to the Optional Redemption Date. Notice of redemption having been given as provided in the Indenture, the Notes called for redemption shall, on the Optional Redemption Date, become due and payable at the Optional Redemption Price, plus
accrued and unpaid interest and Additional Amounts, if any, to, but excluding, the Optional Redemption Date. 

Section 1.4B Redemption Upon Changes in Withholding Tax. 

The provisions of Section 15.01 of the Base Indenture shall apply to the Notes. The redemption price for any redemption pursuant to this
Section 1.4B shall be paid prior to 12:00 noon, London time, on the applicable redemption date or at such later time as is then permitted by the rules of the Common Safekeeper applicable to the Notes (if then registered as Global Notes);
provided, that the Company shall deposit or have deposited with the Trustee or the Paying Agent an amount sufficient to pay such redemption price by 10:00 a.m., London time, on the Business Day prior to the date such redemption price is
to be paid. If money sufficient to pay the redemption price of the Notes on the applicable redemption date is deposited with the Trustee or Paying Agent on or before such redemption date as provided herein, then on and after such redemption date,
interest will cease to accrue on the Notes. 
 Section 1.5 Change of Control Triggering Event. 

The following additional covenants shall apply with respect to the Notes so long as any of the Notes remain Outstanding: 

(a) If a Change of Control Triggering Event occurs with respect to any series of the Notes, unless the Company shall have redeemed such series
of the Notes in full, as set forth in Section 1.4A or 1.4B of this Supplemental Indenture, the Company shall have defeased such series of the Notes or have satisfied and discharged such series of the Notes, as set forth in Article XI of
the Base Indenture, the Company shall make an offer (a “Change of Control Offer”) to each Holder of the applicable series of the Notes to repurchase any and all of such Holder’s Notes of such series at a repurchase price in
cash equal to 101% of the aggregate principal amount of the Notes to be repurchased (such principal amount to be equal to €100,000 or any integral multiple of €1,000 in excess thereof), plus accrued and unpaid interest, if any, on the
Notes to be repurchased up to, but excluding, the date of repurchase (the “Change of Control Payment”). Within 30 days following any Change of Control Triggering Event, notice shall be delivered to the Holders of Notes of such
series describing the transaction or transactions that constitute the Change of Control Triggering Event and offering to repurchase such Notes on the date specified in the notice, which date will be no earlier than 15 days and no later than
60 days from the date such notice is delivered (the “Change of Control Payment Date”). Notwithstanding the foregoing, installments of interest whose Stated Maturity is on or prior to the Change of Control Payment Date shall be
payable on the applicable Interest Payment Date to the Holders of such Notes registered as such at the close of business on the applicable regular record date pursuant to the Notes and the Indenture. 

  
 15 

 (b) On the Change of Control Payment Date, the Company shall, to the extent lawful: 

 

	 	(i)	 accept for payment all Notes or portions of Notes of the applicable series properly tendered pursuant to the
Change of Control Offer; 

  

	 	(ii)	 deposit with the Trustee or a paying agent an amount equal to the Change of Control Payment in respect of all
Notes or portions of Notes of the applicable series properly tendered; and 

  

	 	(iii)	 deliver or cause to be delivered to the Trustee the Notes properly accepted, together with an Officer’s
Certificate stating (1) the aggregate principal amount of such series of Notes or portions of such series of Notes being repurchased, (2) that all conditions precedent contained in the Indenture to make a Change of Control Offer have been
complied with and (3) that the Change of Control Offer has been made in compliance with the Indenture. 

 The Company
shall comply in all material respects with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are
applicable in connection with the repurchase of the Notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with this Section 1.5, the Company shall comply
with the applicable securities laws and regulations and shall not be deemed to have breached its obligations under this Section 1.5 by virtue of any such conflict. 

Section 1.6 Events of Default. 

The provisions of Article VI of the Base Indenture shall be applicable to each series of the Notes, except that clauses (1) through
(7) of Section 6.01(a) thereof shall be modified with respect to Notes of a series as follows: 
 (1) default in the payment of the
principal or any premium on such series of Notes when due (whether at maturity, upon acceleration, redemption or otherwise); 
 (2) default
for 30 days in the payment of interest on the Notes of such series when due; 
 (3) (i) failure by the Company to comply with
Section 1.5 of this Supplemental Indenture with respect to such series or (ii) failure by the Company or the Guarantor to observe or perform any term of the Indenture applicable to such series of Notes (other than those referred to in
(1) or (2) above or (3)(i) above) for a period of 90 days after the Company receives a notice of default stating that the Company or the Guarantor is in breach. The notice required under (3)(ii) above must be sent by either the Trustee or
Holders of 25% of the principal amount of the applicable series of Notes; 

  
 16 

 (4) (A) failure by the Company or the Guarantor to pay indebtedness for money borrowed by
the Company or the Guarantor or for which the Company or the Guarantor has guaranteed the payment, in an aggregate principal amount of at least $500,000,000, at the later of final maturity and the expiration of any related applicable grace period
and such defaulted payment shall not have been made, waived or extended within 30 days or (B) acceleration of the maturity of any indebtedness for money borrowed by the Company or the Guarantor or for which the Company or the Guarantor has
guaranteed the payment, in an aggregate principal amount of at least $500,000,000, if such indebtedness has not been discharged in full or such acceleration has not been rescinded or annulled within 30 days; provided, however,
that, if the default under the instrument is cured by the Company or the Guarantor, as applicable, or waived by the holders of the indebtedness, in each case as permitted by the governing instrument, then the Event of Default under the Indenture
caused by such default will be deemed likewise to be cured or waived; 
 (5) the entry by a court having competent jurisdiction of: 

(A) an order for relief in respect of the Company or the Guarantor as debtor in an involuntary proceeding under any applicable
Bankruptcy Law and such order shall remain unstayed and in effect for a period of 60 consecutive days; or 
 (B) a final and non-appealable order appointing a Custodian of the Company or the Guarantor, or ordering the winding up or liquidation of the affairs of the Company or the Guarantor, and such order shall remain unstayed and in
effect for a period of 60 consecutive days; 
 (6) the commencement by the Company or the Guarantor of a voluntary proceeding under any
applicable Bankruptcy Law or the consent by the Company or the Guarantor as debtor to the entry of a decree or order for relief in an involuntary proceeding under any applicable Bankruptcy Law, or the filing by the Company or the Guarantor as debtor
of a consent to an order for relief in any involuntary proceeding under any Bankruptcy Law, or to the appointment of a Custodian or the making by the Company or the Guarantor of an assignment for the benefit of creditors; or 

(7) the Guarantee of the Notes of such series is determined in a final, non-appealable judgment to be
unenforceable or invalid or such Guarantee is asserted in writing by the Company or the Guarantor to no longer be in full force and effect and enforceable in accordance with its terms. 

Section 1.7 Form of Effectuation Instruction for the Notes: 

The Common Service Provider’s form of Effectuation Instruction shall be in substantially the following form: 

Issuer: Thermo Fisher Scientific (Finance I) B.V. 

Currency and nominal Amount: € 

  
 17 

 ISIN: 

Dear Sir/Madam, 
 We hereby
instruct you to effectuate the global note. 
  

	
	Dated:
	
	The Bank of New York Mellon, London Branch
	As Common Service Provider
	
	By: _______________________________________
	Authorized Signatory

 Section 1.8 Effectuation of the Notes 

No Global Note in respect of the Notes shall be valid or obligatory for any purposes until it has been effectuated for or on behalf of the
Common Safekeeper. 
 Section 1.9 Destroy Option 

In the case of a Global Note, the Common Safekeeper may destroy such Global Note in accordance with the normal procedures of the Common
Safekeeper upon maturity and final redemption of such Global Note. 
 ARTICLE II 

MISCELLANEOUS 

Section 2.1 Business Day. 

If any maturity date or earlier date of redemption for any series of Notes falls on a day that is not a Business Day, the required payment
shall be made on the next Business Day as if it were made on the date the payment to Holders was due and no interest shall accrue on the amount so payable for the period from and after that maturity date or that date of redemption, as the case may
be. 
 Section 2.2 [Reserved]. 

Section 2.3 Confirmation of Indenture. 

The Base Indenture, as supplemented and amended by this Supplemental Indenture, is in all respects ratified and confirmed, and the Base
Indenture, this Supplemental Indenture and all indentures supplemental thereto shall be read, taken and construed as one and the same instrument. 

  
 18 

 Section 2.4 Concerning the Trustee. 

In carrying out its responsibilities hereunder, the Trustee shall have all of the rights, protections and immunities which it possesses under
the Indenture. The recitals contained herein and in the Notes, except the Trustee’s certificate of authentication, shall be taken as the statements of the Company, and the Trustee assumes no responsibility for their correctness. The Trustee
makes no representations as to the validity or sufficiency of this Supplemental Indenture or of the Notes. The Trustee shall not be accountable for the use or application by the Company of the Notes or the proceeds thereof. 

Section 2.5 Governing Law. 

This Supplemental Indenture and the Notes shall be deemed to be a contract made under the internal laws of the State of New York, and for all
purposes shall be construed in accordance with the laws of said State. 
 Section 2.6 Separability. 

In case any provision in this Supplemental Indenture shall for any reason be held to be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 2.7 Counterparts. 

This Supplemental Indenture may be executed in any number of counterparts each of which shall be an original, but such counterparts shall
together constitute but one and the same instrument. The exchange of copies of this Supplemental Indenture and of signature pages by facsimile or electronic format (e.g., “.pdf” or “.tif”) transmission shall constitute effective
execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. 

The words “execution,” “signed,” “signature,” and words of like import in this Supplemental Indenture, the
Indenture or any agreement entered into in connection herewith shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually
executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State
Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act (e.g. DocuSign). Without limitation to the foregoing, and anything in the Indenture to the contrary notwithstanding, (a) any
Officer’s Certificate, Authentication Order, Opinion of Counsel, Security, certificate of authentication appearing on or attached to any Security, or other certificate, opinion of counsel, instrument, agreement or other document delivered
pursuant to the Indenture may be executed, attested and transmitted by any of the foregoing electronic means and formats and (b) all references in Section 2.04 or elsewhere in the Base Indenture to the execution, attestation or
authentication of any Security or any certificate of authentication appearing on or attached to any Security by means of a manual or facsimile signature shall be deemed to include signatures that are made or transmitted by any of the foregoing
electronic means or formats. 

  
 19 

 Section 2.8 No Benefit. 

Nothing in this Supplemental Indenture, express or implied, shall give to any Person other than the parties hereto and their successors or
assigns, and the Holders, any benefit or legal or equitable rights, remedy or claim under this Supplemental Indenture or the Base Indenture. 

Section 2.9 Power of Attorney. 

If any party to this Supplemental Indenture is represented by an attorney or attorneys in connection with the signing and/or execution and/or
delivery of this Supplemental Indenture or any agreement or document referred to herein or made pursuant hereto, including any Note, and the relevant power or powers of attorney is or are expressed to be governed by the laws of a particular
jurisdiction, it is hereby expressly acknowledged and accepted by the other parties hereto that such laws shall govern the existence and extent of such attorney’s or attorneys’ authority and the effects of the exercise thereof. 

Section 2.10 Electronic Means. 

The Trustee shall have the right to accept and act upon instructions, including funds transfer instructions (“Instructions”)
given pursuant to the Indenture and delivered using Electronic Means; provided, however, that the Company shall provide to the Trustee an incumbency certificate listing officers with the authority to provide such Instructions (“Authorized
Officers”) and containing specimen signatures of such Authorized Officers, which incumbency certificate shall be amended by the Company whenever a person is to be added or deleted from the listing. If the Company elects to give the
Trustee Instructions using Electronic Means and the Trustee in its discretion elects to act upon such Instructions, the Trustee’s understanding of such Instructions shall be deemed controlling. The Company understands and agrees that the
Trustee cannot determine the identity of the actual sender of such Instructions and that the Trustee shall conclusively presume that directions that purport to have been sent by an Authorized Officer listed on the incumbency certificate provided to
the Trustee have been sent by such Authorized Officer. The Company shall be responsible for ensuring that only Authorized Officers transmit such Instructions to the Trustee and that the Company and all Authorized Officers are solely responsible
to safeguard the use and confidentiality of applicable user and authorization codes, passwords and/or authentication keys upon receipt by the Company. The Trustee shall not be liable for any losses, costs or expenses arising directly or
indirectly from the Trustee’s reliance upon and compliance with such Instructions notwithstanding such directions conflict or are inconsistent with a subsequent written instruction. The Company agrees: (i) to assume all risks arising
out of the use of Electronic Means to submit Instructions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized Instructions, and the risk of interception and misuse by third parties; (ii) that it is fully
informed of the protections and risks associated with the various methods of transmitting Instructions to the Trustee and that there may be more secure methods of transmitting Instructions than the method(s) selected by the Issuer; (iii) that
the security procedures (if any) to be followed in connection with its transmission of Instructions provide to it a commercially reasonable degree of protection in light of its particular needs and circumstances; and (iv) to notify the Trustee
immediately upon learning of any compromise or unauthorized use of the security procedures. 

  
 20 

 Section 2.11 OFAC Certification and Covenants. 

(a) The Company covenants and represents that neither it nor any of its subsidiaries, directors or officers are the target or subject of any
sanctions enforced by the US Government, (including, the Office of Foreign Assets Control of the US Department of the Treasury (“OFAC”)), the United Nations Security Council, the European Union, or Her Majesty’s Treasury
(collectively “Sanctions”). 
 (b) The Company covenants and represents that neither it nor any of its subsidiaries,
directors or officers will use any part of the proceeds received in connection with the Indenture and the Notes to be issued thereunder or any other of the transaction documents to fund or facilitate any activities of or business with any person
who, at the time of such funding or facilitation, to the Company’s knowledge after due inquiry, is the subject or target of Sanctions. It is acknowledged and agreed that the covenants and representations in this Section 2.11 are only
sought and given to the extent that to do so would not be unenforceable by or in respect of that person by reason of breach of (i) any provision of Council Regulation (EC) No 2271/96 of 22 November 1996 (or any law or regulation
implementing such Regulation in any member state of the European Union) or (ii) Council Regulation (EC) No 2271/96 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (or any law or
regulation implementing such Regulation in the United Kingdom). 
 [Signatures on Following Page] 

 

  
 21 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed all as of the day and year first above written. 
  

			
	THERMO FISHER SCIENTIFIC (FINANCE I)
	B.V.
		
	By:	 	 /s/ Anthony H. Smith 

		 	 Name:   Anthony H. Smith

		 	 Title:   Managing Director

	
	THERMO FISHER SCIENTIFIC INC.
		
	By:	 	 /s/ Anthony H. Smith

		 	 Name:   Anthony H. Smith

		 	 Title:   Vice President, Tax and Treasury and Treasurer

  
 [Signature Page to
Fourth Supplemental Indenture] 

 
			
	THE BANK OF NEW YORK MELLON
	TRUST COMPANY, N.A., as Trustee
		
	By:	 	 /s/ Ann Dolezal

		 	 Name:   Ann Dolezal

		 	 Title:   Vice President

  

  
 [Signature Page to
Fourth Supplemental Indenture] 

 EXHIBIT A 

THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE NOMINEE OF THE ENTITY
APPOINTED AS COMMON SAFEKEEPER FOR EUROCLEAR BANK S.A./N.V. (“EUROCLEAR”) AND CLEARSTREAM BANKING S.A. (“CLEARSTREAM”). 

FLOATING RATE SENIOR NOTES DUE 2023 
  

			
	 No. [ ]
	  	€[ ]

 ISIN XS2407911705 

THERMO FISHER SCIENTIFIC (FINANCE I) B.V. 

(a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the
Netherlands having its corporate seat (statutaire zetel) in Breda, The Netherlands) 
 promises to pay to [ ] or registered assigns, the principal
sum of [ ] Euro on November 18, 2023 (the “Maturity Date”). 
 Interest Payment Dates: February 18, May 18, August 18
and November 18, commencing on February 18, 2022 and ending on the Maturity Date 
 Record Dates: The Clearing System Business Day immediately
preceding the applicable Interest Payment Date. 
 Each holder of this Security (as defined below), by accepting the same, agrees to and
shall be bound by the provisions hereof and of the Indenture described herein, and authorizes and directs the Trustee described herein on such holder’s behalf to be bound by such provisions. Each holder of this Security hereby waives all notice
of the acceptance of the provisions contained herein and in the Indenture and waives reliance by such holder upon said provisions. 
 This
Security shall not be entitled to any benefit under the Indenture, or be valid or become obligatory for any purpose, until the Certificate of Authentication hereon shall have been signed by or on behalf of the Trustee and until it has been
effectuated for and on behalf of the Common Safekeeper. The provisions of this Security are continued on the reverse side hereof, and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 

This is to certify that the person whose name is entered in the register is the holder of the aggregate nominal amount of €[ ]. 

  
 A-1 

 IN WITNESS WHEREOF, the Company has caused this instrument to be signed in accordance with Section 2.04
of the Base Indenture. 
 Date: [ ] 
  

			
	THERMO FISHER SCIENTIFIC (FINANCE I)
	B.V.
		
	By:	 	
                

		 	Name:
		 	Title:

  
 A-2 

 CERTIFICATE OF AUTHENTICATION 

This is one of the Floating Rate Senior Notes due 2023 issued by Thermo Fisher Scientific (Finance I) B.V. of the series designated therein, referred to in
the within-mentioned Indenture. 
 Date: [ ] 
  

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee
		
	By:	 	  

		 	Authorized Signatory

  
 A-3 

 EFFECTUATED for and on behalf of EUROCLEAR BANK S.A./N.V., as Common Safekeeper, without recourse, warranty
or liability. 
  

			
	EUROCLEAR BANK S.A./N.V., as Common Safekeeper
		
	By:	 	
                    

		
		 	Authorized Signatory:
		
		 	Dated:

  
 A-4 

 Thermo Fisher Scientific (Finance I) B.V. 

Floating Rate Senior Notes due 2023 
 This
security is one of a duly authorized series of debt securities of Thermo Fisher Scientific (Finance I) B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the
Netherlands, with its corporate seat (statutaire zetel) at Breda, the Netherlands, and its registered office at Takkebijsters 1, 4817 BL Breda, the Netherlands, registered with the Dutch Trade Register of the Chamber of Commerce under number
66428319 (the “Company”), issued or to be issued in one or more series under and pursuant to an Indenture for the Company’s unsecured debt securities, dated as of August 9, 2016 (the “Base Indenture”),
duly executed and delivered by and among the Company, Thermo Fisher Scientific Inc., a Delaware corporation (the “Guarantor”), and The Bank of New York Mellon Trust Company, N.A. (the “Trustee”), as supplemented by
the Fourth Supplemental Indenture, dated as of November 18, 2021 (the “Supplemental Indenture”), among the Company, the Guarantor and the Trustee. The Securities are subject to a Paying Agency Agreement, dated as of
November 18, 2021 (the “Paying Agency Agreement”), between the Company and The Bank of New York Mellon, London Branch, as paying agent (the “Paying Agent”) and a Calculation Agency Agreement, dated as of
November 18, 2021 (the “Calculation Agency Agreement”), between the Company and The Bank of New York Mellon, London Branch, as calculation agent (the “Calculation Agent”). The Base Indenture as supplemented and
amended by the Supplemental Indenture is referred to herein as the “Indenture.” By the terms of the Base Indenture, the debt securities issuable thereunder are issuable in series that may vary as to amount, date of maturity, rate of
interest and in other respects as provided in the Base Indenture. This security is one of the series designated on the face hereof (individually, a “Security,” and collectively, the “Securities”), and reference is
hereby made to the Indenture for a description of the rights, limitations of rights, obligations, duties and immunities of the Trustee, the Company, the Guarantor and the holders of the Securities (the “Securityholders”).
Capitalized terms used herein and not otherwise defined shall have the meanings given them in the Base Indenture or the Supplemental Indenture, as applicable. 

1. Interest. The Securities will bear interest from November 18, 2021 or from the immediately preceding Interest Payment Date to
which interest has been paid. Interest on the Securities shall be payable quarterly in arrears on February 18, May 18, August 18 and November 18 of each year (each, a “Interest Payment Date”), commencing on
February 18, 2022; provided, that, if any Interest Payment Date would be a day that is not a Business Day, such Interest Payment Date shall be the next succeeding day that is a Business Day (and no additional interest will accrue or
otherwise accumulate on the amount payable for the period from and after such Interest Payment Date); except that if such next succeeding Business Day falls in the next succeeding calendar month, such Interest Payment Date shall be the immediately
preceding Business Day. The Securities shall bear interest at a rate equivalent to the 3-month EURIBOR (the “Base Rate”) plus 0.200% per annum, as calculated by the Calculation Agent;
provided, however, that the minimum interest rate shall be zero. The interest rate on the Securities will be reset quarterly on February 18, May 18, August 18 and November 18 of each year (each, an “Interest
Reset Date”), commencing on February 18, 2022; provided, that, if any Interest Reset Date would be a day that is not a Business Day, such Interest Reset Date shall be 

  
 A-5 

 
the next succeeding day that is a Business Day, except that if such next succeeding Business Day falls in the next succeeding calendar month, such Interest Reset Date shall be the immediately
preceding Business Day. The initial Base Rate for the Securities in effect from November 18, 2021 to, but excluding, the first Interest Reset Date will be the 3-month EURIBOR in effect on
November 16, 2021. The interest rate on the Securities will be determined on the second TARGET2 Business Day preceding the applicable Interest Reset Date (a “EURIBOR Interest Determination Date”). Interest on the Securities
will be computed on the basis of a 360-day year and the actual number of days in the period for which interest is being calculated. 

The Base Rate that takes effect on any Interest Reset Date shall be equal to the interest rate for deposits in euro designated as
“EURIBOR” and sponsored jointly by the European Banking Federation and ACI — the Financial Market Association (or any company established by the joint sponsors for purposes of compiling and publishing that rate) on each EURIBOR
Interest Determination Date, and will be determined by the Calculation Agent in accordance with the following provisions: 
 i. EURIBOR will
be the offered rate for deposits in euro having a maturity of three months, as that rate appears on Reuters Page EURIBOR01 as of 11:00 A.M., Brussels time, on the relevant EURIBOR Interest Determination Date. 

ii. If the rate described in clause (i) above does not appear on Reuters Page EURIBOR01, EURIBOR will be determined on the basis of the
rates, at approximately 11:00 A.M., Brussels time, on the relevant EURIBOR Interest Determination Date, at which deposits of the following kind are offered to prime banks in the Euro-Zone interbank market by the principal Euro-Zone office of
each of four major banks in that market selected by the Company: euro deposits having a maturity of three months beginning on such Interest Reset Date and in a principal amount of not less than €1,000,000 that is representative for a single
transaction in such market at such time. The Company will request the principal Euro-Zone office of each of these banks to provide to the Paying Agent and Calculation Agent a quotation in writing of its rate. If at least two quotations are provided
in writing, EURIBOR for such EURIBOR Interest Determination Date will be the arithmetic mean (rounded upwards in accordance with Section 1.2(3)(d) of the Supplemental Indenture) of such quotations calculated by the Calculation Agent. The
Company will ensure that the Calculation Agent is provided with appropriate contact details of the relevant personnel at each of the reference banks that the Calculation Agent will be requested to contact to provide such quotation of its rates. 

iii. If fewer than two quotations are provided as described in clause (ii) above, EURIBOR for the relevant EURIBOR Interest Determination
Date will be the arithmetic mean of the rates for loans of the following kind to leading Euro-Zone banks quoted in writing, at approximately 11:00 A.M., Brussels time, on such EURIBOR Interest Determination Date, by three major banks in the
Euro-Zone selected by the Company: loans of euro having a maturity of three months beginning on such Interest Reset Date and in a principal amount of not less than €1,000,000 that is representative for a single transaction in such market at
such time. 

  
 A-6 

 iv. If fewer than three banks selected by the Company are quoting as described in
clause (iii) above, EURIBOR shall be the EURIBOR then in effect on such EURIBOR Interest Determination Date. 
 Notwithstanding the
foregoing, if the Company, in its sole discretion, determines that EURIBOR has been permanently discontinued, or the reference to EURIBOR becomes illegal or most other debt obligations similar to this Security have converted away from EURIBOR to a
new reference rate, the Calculation Agent shall use, as directed in writing by the Company, as a substitute for EURIBOR for each future interest determination date, the alternative reference rate (the “Alternative Rate”) selected by
a central bank, reserve bank, monetary authority or any similar institution (including any committee or working group thereof) that is consistent with accepted market practice regarding a substitute for EURIBOR. As part of such substitution, the
calculation agent will, as directed in writing by the Company, make such adjustments (the “Adjustments”) to the Alternative Rate and/or the spread thereon, as well as the business day convention, interest determination dates and
related provisions and definitions, in each case that are consistent with accepted market practice for the use of such Alternative Rate for debt obligations such as this Security. If the Company determines there is no clear market consensus as to
whether any rate has replaced EURIBOR in customary market usage, the Company may appoint an independent financial advisor (the “IFA”) to determine an appropriate Alternative Rate, and any Adjustments, and the decision of the IFA
shall be binding on the Company, the Calculation Agent, the Trustee and the Holders. If, however, the Company determines that EURIBOR has been discontinued, but for any reason an Alternative Rate has not been determined, the rate of EURIBOR for the
next interest period shall be equal to such rate on the interest determination date when EURIBOR was last available on Reuters Page EURIBOR 01, as determined by the Calculation Agent. 

Upon the request of any Securityholder to the Calculation Agent, the Calculation Agent will provide the interest rate then in effect on the
Securities and, if determined, the interest rate that will become effective on the next Interest Reset Date. 
 All percentages resulting
from any calculation with respect to the Securities will be rounded upward or downward, as appropriate, to the next higher or lower one hundred-thousandth of a percentage point (e.g., 9.876541% (or .09876541) being rounded down to 9.87654% (or
..0987654) and 9.876545% (or .09876545) being rounded up to 9.87655% (or .0987655)). All amounts used in or resulting from any calculation with respect to the Securities will be rounded upward or downward, as appropriate, to the nearest cent, in the
case of euro amounts or U.S. dollars, or to the nearest corresponding hundredth of a unit, in the case of a currency other than euro amounts or U.S. dollars, with one-half cent or one-half of a corresponding hundredth of a unit or more being rounded upward. 

  
 A-7 

 In no event shall the Calculation Agent be responsible for determining the Alternative Rate
or any substitute for EURIBOR, or for making any Adjustments to any alternative benchmark or spread thereon, the business day convention, interest determination dates or any other relevant methodology for calculating any such substitute or successor
benchmark. In connection with the foregoing, the Calculation Agent will be entitled to conclusively rely on any determinations made by the Company and will have no liability for such actions taken at the direction of the Company. 

2. Method of Payment. The Company will pay interest on the Securities (except defaulted interest), if any, to the persons in whose name
such Securities are registered at the close of business on the regular record date referred to on the facing page of this Security for such interest installment. In the event that the Securities or a portion thereof are called for redemption
pursuant to Section 1.4B of the Supplemental Indenture or there is a Change of Control Offer, and the Optional Redemption Date or the Change of Control Payment Date, as applicable, is subsequent to a regular record date with respect to any
Interest Payment Date and prior to such Interest Payment Date, interest on such Securities shall instead be paid upon presentation and surrender of such Securities as provided in the Indenture. Subject to Section 1.2(13) of the Supplemental
Indenture, all payments of principal of, and interest (including Additional Amounts, if any) and premium (if any) on, the Securities shall be payable in euro. 

3. Paying Agent, Calculation Agent and Security Registrar. Initially, The Bank of New York Mellon, London Branch, shall act as the
Paying Agent and Calculation Agent, in accordance with the terms of the Paying Agency Agreement and the Calculation Agency Agreement, respectively, and the Trustee shall act as Security Registrar. Upon prior notice to the Trustee, the Company may
change or appoint any Paying Agent, Security Registrar or Calculation Agent without notice to any Securityholder. The Company, the Guarantor or any of the Guarantor’s Subsidiaries may act in any such capacity. 

4. Indenture. The terms of the Securities include those stated in the Indenture and those made part of the Indenture by reference to
the Trust Indenture Act of 1939, as amended (“TIA”) as in effect on the date the Indenture is qualified. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and TIA for a statement of such
terms. In the event of a conflict between the terms of the Securities and the terms of the Indenture, the terms of the Indenture shall prevail. The Securities are unsecured general obligations of the Company and constitute the series designated on
the face hereof as the “Floating Rate Senior Notes due 2023”, initially limited to €1,700,000,000 in aggregate principal amount. The Company shall furnish to any Securityholder upon written request and without charge a copy of the
Base Indenture and the Supplemental Indenture. Requests may be made to: Thermo Fisher Scientific Inc., 168 Third Avenue, Waltham, Massachusetts 02451, Attention: Michael A. Boxer. 

5. No Optional Redemption. Except as set forth in Section 1.4B of the Supplemental Indenture, the Company may not redeem the
Securities of this series prior to the Maturity Date. The Company shall not be required to make sinking fund payments with respect to the Securities. 

6. Redemption Upon Changes in Withholding Taxes; Payment of Additional Amounts. The provisions of Sections 15.01 and 15.02 of the
Base Indenture and Sections 1.3 and 1.4B of the Supplemental Indenture shall apply to the Securities. 

  
 A-8 

 Whenever the payment of the principal of or interest or any other amounts on, or in respect
of, the Securities is mentioned, in any context, such mention shall be deemed to include mention of the payment of Additional Amounts to the extent that, in such context, Additional Amounts are, were or would be payable in respect thereof pursuant
to the terms of the Indenture, and express mention of the payment of Additional Amounts in any provision of the Securities shall not be construed as excluding the payment of Additional Amounts in those provisions where such express mention is not
made. 
 7. Change of Control Triggering Event. Upon the occurrence of a Change of Control Triggering Event, unless the Company has
redeemed this Security or the Company has defeased this Security or satisfied and discharged this Security, the holder of this Security shall have the right to require that the Company purchase all or a portion (such principal amount to be equal to
€100,000 or any integral multiple of €1,000 in excess thereof) of this Security at a purchase price equal to 101% of the aggregate principal amount repurchased plus accrued and unpaid interest, if any, on the amount to be repurchased up to
but excluding the date of purchase. Within 30 days following any Change of Control Triggering Event, the Company shall send, by first class mail, a notice to each Holder, in accordance with Section 1.5 of the Supplemental Indenture, with a
copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. 
 8. Denominations, Transfer, Exchange. The
Securities are in registered form without coupons in the denominations of €100,000 or any integral multiple of €1,000 in excess thereof. The transfer of Securities may be registered and Securities may be exchanged as provided in the
Indenture. The Securities may be presented for exchange or for registration of transfer (duly endorsed or with the form of transfer endorsed thereon duly executed if so required by the Company or the Security Registrar) at the office of the Paying
Agent or at the office of any transfer agent designated by the Company for such purpose(or otherwise in accordance with the applicable procedures of Euroclear and Clearstream). No service charge shall be made for any registration of transfer or
exchange, but a Securityholder may be required to pay any applicable taxes or other governmental charges. 
 9. Persons Deemed
Owners. The registered Securityholder may be treated as its owner for all purposes. 
 10. Repayment to the Company. Any funds or
Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of, premium, if any, or interest on the Securities that are not applied but remain unclaimed by the holders of
such Securities for at least one year after the date upon which the principal of, premium, if any, or interest on such Securities shall have respectively become due and payable, shall be repaid to the Company, as applicable, or (if then held by the
Company) shall be discharged from such trust. After return to the Company, Holders entitled to the money or securities must look to the Company, as applicable, for payment as unsecured general creditors. 

  
 A-9 

 11. Amendments, Supplements and Waivers. The Indenture permits, with certain
exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the Guarantor and the rights of the Holders of the Securities to be affected under the Indenture at any time by the Company,
the Guarantor and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding to be affected. The Indenture also contains provisions permitting the Holders of a majority in principal amount
of the Securities at the time Outstanding, on behalf of the Holders of all Securities, to waive compliance by the Company or the Guarantor with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences.
Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in
lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
 12. Defaults and Remedies. If an Event
of Default with respect to the Securities occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the Securities then Outstanding, by notice in writing to the Company (and to the Trustee if notice is
given by such holders), may declare the entire principal of, premium, if any, and accrued interest, if any, of such Securities due and payable immediately. Subject to the terms of the Indenture, if an Event of Default under the Indenture shall occur
and be continuing, the Trustee shall be under no obligation to exercise any of its rights or powers under the Indenture at the request or direction of any of the holders, unless such holders have offered the Trustee indemnity satisfactory to it.
Upon satisfaction of certain conditions set forth in the Indenture, the holders of a majority in principal amount of the Outstanding Securities shall have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities. 
 13. Trustee,
Paying Agent and Security Registrar May Hold Securities. The Trustee, subject to certain limitations imposed by the TIA, or any Paying Agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of
Securities with the same rights it would have if it were not Trustee, Paying Agent or Security Registrar. 
 14. No Recourse Against
Others. No recourse under or upon any obligation, covenant or agreement of the Indenture, or of any Security, or for any claim based thereon or otherwise in respect hereof or thereof, shall be had against any incorporator, stockholder, officer
or director, past, present or future as such, of the Company or the Guarantor or of any predecessor or successor corporation, either directly or through the Company or the Guarantor or any such predecessor or successor corporation, whether by virtue
of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that the Indenture and the obligations issued hereunder and thereunder are solely corporate obligations, and
that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or the Guarantor or of any predecessor or successor corporation, or any of them,
because of the creation of the indebtedness authorized by the Indenture, or under or by reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom; and that any and all such personal
liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of
the indebtedness authorized by the Indenture, or under or by reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as
a consideration for, the acceptance of the Securities. 

  
 A-10 

 15. Discharge of Indenture. The Indenture contains certain provisions pertaining to
discharge and defeasance, which provisions shall for all purposes have the same effect as if set forth herein. 
 16. Authentication.
This Security shall not be valid until the Trustee signs the certificate of authentication attached to the other side of this Security. 

17. Guarantee. This Security is fully and unconditionally guaranteed by the Guarantor, as provided in Article XIV of the Base
Indenture. 
 18. Abbreviations. Customary abbreviations may be used in the name of a Securityholder or an assignee, such as: TEN
COM(= tenants in common), TEN ENT (=tenants by the entireties), JT TEN(= joint tenants with right of survivorship and not as tenants in common), CUST (=Custodian), and U/G/M/A(= Uniform Gifts to Minors Act). 

19. Governing Law. The Base Indenture, the Supplemental Indenture and this Security shall be deemed to be a contract made under the
internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

  
 A-11 

 ASSIGNMENT FORM 

To assign this Security, fill in the form below: (I) or (we) assign and transfer this Security to 

 
  

(Insert assignee’s soc. sec. or tax I.D. no.) 
  

 
  

 
  

 
  

 
 (Print or type assignee’s name,
address and zip code) 
 and irrevocably appoint _______________________________________________________________________________________ agent to transfer
this Security on the books of the Company. The agent may substitute another to act for him. 
 Date: ______________________________ 

 

	
	Your Signature _____________________________
	(Sign exactly as your name appears on the face of this Security)

 Signature Guarantee: _____________________________________ 

  
 A-12 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Security purchased by the Company pursuant to Section 1.5 of the Supplemental Indenture, check the box:

  

	☐	 1.5 Change of Control Triggering Event 

If you want to elect to have only part of this Security purchased by the Company pursuant to Section 1.5 of the Supplemental Indenture,
state the amount: €_______________ 
  

			
	 Date: _________________________
	  	 Your Signature ______________________________________

		  	(Sign exactly as your name appears on the face of this Security)

 Tax I.D. Number: __________________________________ 

Signature Guarantee: ____________________________________________ 

(Signature must be guaranteed by a 

participant in a recognized signature 

guarantee medallion program) 

  
 A-13 

 NOTATION OF GUARANTEE 

For value received, Thermo Fisher Scientific Inc. hereby absolutely, unconditionally and irrevocably guarantees to the holder of this Security
the payment of principal of, premium, if any, and interest on, the Security upon which this Guarantee is set forth in the amounts and at the time when due and payable whether by declaration thereof, or otherwise, and interest on the overdue
principal and interest, if any, of such Security, if lawful, to the holder of such Security and the Trustee on behalf of the Holders, all in accordance with and subject to the terms and limitations of such Security and Article XIV of the
Indenture. This Guarantee will not become effective until the Trustee or Authenticating Agent duly executes the certificate of authentication on this Security and until this Security has been effectuated for and on behalf of the Common Safekeeper.
This Guarantee shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict of law principles thereof. 

Dated: [ ] 
  

			
	THERMO FISHER SCIENTIFIC INC.
		
	By:	 	
                

	Name:	 	
	Title:	 	

  
 A-14 

 EXHIBIT B 

THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE NOMINEE OF THE ENTITY
APPOINTED AS COMMON SAFEKEEPER FOR EUROCLEAR BANK S.A./N.V. (“EUROCLEAR”) AND CLEARSTREAM BANKING S.A. (“CLEARSTREAM”). 

[ ]%1 SENIOR NOTES DUE [ ]2

  

			
	 No. [ ]
	  	€[ ]

 ISIN [ ]3 

THERMO FISHER SCIENTIFIC (FINANCE I) B.V. 

(a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the
Netherlands having its corporate seat (statutaire zetel) in Breda, The Netherlands) 
 promises to pay to [ ] or registered assigns, the principal
sum of [ ] Euro on [ ]4. 
 Interest Payment Date: [ ] 

Record Date: The Clearing System Business Day immediately preceding the applicable Interest Payment Date. 

Each holder of this Security (as defined below), by accepting the same, agrees to and shall be bound by the provisions hereof and of the
Indenture described herein, and authorizes and directs the Trustee described herein on such holder’s behalf to be bound by such provisions. Each holder of this Security hereby waives all notice of the acceptance of the provisions contained
herein and in the Indenture and waives reliance by such holder upon said provisions. 
 This Security shall not be entitled to any benefit
under the Indenture, or be valid or become obligatory for any purpose, until the Certificate of Authentication hereon shall have been signed by or on behalf of the Trustee and until it has been effectuated for and on behalf of the Common Safekeeper.
The provisions of this Security are continued on the reverse side hereof, and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 

This is to certify that the person whose name is entered in the register is the holder of the aggregate nominal amount of €[ ]. 

 

	1 	 2023 Notes: 0.000; and 2025 Notes: 0.000 

	2 	 2023 Notes: 2023; and 2025 Notes: 2025 

	3 	 2023 Notes: XS2407913586; and 2025 Notes: XS2407914394 

	4 	 2023 Notes: November 18, 2023; and 2025 Notes: November 18, 2025 

  
 B-1 

 IN WITNESS WHEREOF, the Company has caused this instrument to be signed in accordance with Section 2.04
of the Base Indenture. 
 Date: [ ] 
  

			
	THERMO FISHER SCIENTIFIC (FINANCE
	I) B.V.
		
	By:	 	
                

		 	Name:
		 	Title:

  
 B-2 

 CERTIFICATE OF AUTHENTICATION 

This is one of the [ ]5 issued by Thermo Fisher Scientific (Finance I) B.V. of the series designated
therein, referred to in the within-mentioned Indenture. 
 Date: [ ] 

 

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
	as Trustee
		
	By:	 	
                     
   

		 	Authorized Signatory

  

	5 	 2023 Notes: 0.000% Senior Notes due 2023; and 2025 Notes: 0.000% Senior Notes due 2025 

  
 B-3 

 EFFECTUATED for and on behalf of EUROCLEAR BANK S.A./N.V., as Common Safekeeper, without recourse, warranty
or liability. 
  

			
	EUROCLEAR BANK S.A./N.V., as Common Safekeeper
		
	By:	 	             

		 	Authorized Signatory:
		 	Dated:

  
 B-4 

 Thermo Fisher Scientific (Finance I) B.V. 

[ ]6 

This security is one of a duly authorized series of debt securities of Thermo Fisher Scientific (Finance I) B.V., a private limited liability company
(besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, with its corporate seat (statutaire zetel) at Breda, the Netherlands, and its registered office at Takkebijsters 1, 4817 BL Breda,
the Netherlands, registered with the Dutch Trade Register of the Chamber of Commerce under number 66428319 (the “Company”), issued or to be issued in one or more series under and pursuant to an Indenture for the Company’s
unsecured debt securities, dated as of August 9, 2016 (the “Base Indenture”), duly executed and delivered by and among the Company, Thermo Fisher Scientific Inc., a Delaware corporation (the “Guarantor”) and
The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), as supplemented by the Fourth Supplemental Indenture, dated as of November 18, 2021 (the “Supplemental Indenture”), among the
Company, the Guarantor and the Trustee. The Notes are subject to a Paying Agency Agreement, dated as of November 18, 2021 (the “Paying Agency Agreement”), between the Company and The Bank of New York Mellon, London Branch, as
paying agent (the “Paying Agent”). The Base Indenture as supplemented and amended by the Supplemental Indenture is referred to herein as the “Indenture.” By the terms of the Base Indenture, the debt securities
issuable thereunder are issuable in series that may vary as to amount, date of maturity, rate of interest and in other respects as provided in the Base Indenture. This security is one of the series designated on the face hereof (individually, a
“Security,” and collectively, the “Securities”), and reference is hereby made to the Indenture for a description of the rights, limitations of rights, obligations, duties and immunities of the Trustee, the Company,
the Guarantor and the holders of the Securities (the “Securityholders”). Capitalized terms used herein and not otherwise defined shall have the meanings given them in the Base Indenture or the Supplemental Indenture, as applicable.

 1. Interest. The Company promises to pay interest on the principal amount of this Security at an annual rate of [ ]%7. The Company will pay interest annually in arrears on [ ] of each year (each such day, an “Interest Payment Date”) until the principal is paid or made available for payment. If any
Interest Payment Date, redemption date or maturity date of this Security is not a Business Day, then payment of interest or principal (and premium, if any) shall be made on the next succeeding Business Day with the same force and effect as if made
on the date such payment was due, and no interest shall accrue for the period after such date to the date of such payment on the next succeeding Business Day. Interest on the Securities will accrue from the most recent date to which interest has
been paid or duly made available for payment or, if no interest has been paid, from the date of issuance; provided that, if there is no existing Default in the payment of interest, and if this Security is authenticated between a regular
record 
  

	6 	 2023 Notes: 0.000% Senior Notes due 2023; and 2025 Notes: 0.000% Senior Notes due 2025 

	7 	 2023 Notes: 0.000%; and 2025 Notes: 0.000% 

  
 B-5 

 
date referred to on the face hereof and the next succeeding Interest Payment Date, interest shall accrue from such next succeeding Interest Payment Date; and provided, further, that the
first Interest Payment Date shall be [ ]. Interest on the Securities shall be computed on the basis of an ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of ICMA) day count convention. In order to provide for all payments due on the Securities as
the same shall become due, the Company shall cause to be paid to the Paying Agent, no later than 10:00 a.m. London time on the Business Day prior the payment date of each Security, at such bank as the Paying Agent shall previously have notified to
the Company, in immediately available funds sufficient to meet all payments due on such Securities. 
 2. Method of Payment. The
Company will pay interest on the Securities (except defaulted interest), if any, to the persons in whose name such Securities are registered at the close of business on the regular record date referred to on the facing page of this Security for such
interest installment. In the event that the Securities or a portion thereof are called for redemption pursuant to Sections 1.4A or 1.4B of the Supplemental Indenture or there is a Change of Control Offer, and the Optional Redemption Date or Change
of Control Payment Date, as applicable, is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Securities shall instead be paid upon presentation and surrender of
such Securities as provided in the Indenture. Subject to Section 1.2(13) of the Supplemental Indenture, all payments of principal of, and interest (including Additional Amounts, if any) and premium (if any) on, the Securities shall be payable
in euro. 
 3. Paying Agent and Registrar. Initially, The Bank of New York Mellon, London Branch, shall act as the Paying Agent in
accordance with the terms of the Paying Agency Agreement and the Trustee shall act as Security Registrar. Upon prior notice to the Trustee, the Company may change or appoint any Paying Agent or Security Registrar without notice to any
Securityholder. The Company, the Guarantor or any of the Guarantor’s Subsidiaries may act in any such capacity. 
 4. Indenture.
The terms of the Securities include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939, as amended (“TIA”), as in effect on the date the Indenture is qualified. The
Securities are subject to all such terms, and Securityholders are referred to the Indenture and TIA for a statement of such terms. In the event of a conflict between the terms of the Securities and the terms of the Indenture, the terms of the
Indenture shall prevail. The Securities are unsecured general obligations of the Company and constitute the series designated on the face hereof as the “[ ]8,” initially limited to
€[ ]9 in aggregate principal amount. The Company shall furnish to any Securityholder upon written request and without charge a copy of the Base Indenture and the Supplemental Indenture.
Requests may be made to: Thermo Fisher Scientific Inc., 168 Third Avenue, Waltham, Massachusetts 02451, Attention: Michael A. Boxer. 

 

	8 	 2023 Notes: 0.000% Senior Notes due 2023; and 2025 Notes: 0.000% Senior Notes due 2025 

	9 	 2023 Notes: 550,000,000; and 2025 Notes: 550,000,000 

  
 B-6 

 5. Redemption. The Securities may be redeemed at the option of the Company prior to
the maturity date, as provided in Section 1.4A and 1.4B of the Supplemental Indenture. The Company shall not be required to make sinking fund payments with respect to the Securities. 

6. Redemption Upon Changes in Withholding Taxes; Payment of Additional Amounts. The provisions of Sections 15.01 and 15.02 of the
Base Indenture and Sections 1.3 and 1.4B of the Supplemental Indenture shall apply to the Securities. 
 Whenever the payment of the
principal of or interest or any other amounts on, or in respect of, the Securities is mentioned, in any context, such mention shall be deemed to include mention of the payment of Additional Amounts to the extent that, in such context, Additional
Amounts are, were or would be payable in respect thereof pursuant to the terms of the Indenture, and express mention of the payment of Additional Amounts in any provision of the Securities shall not be construed as excluding the payment of
Additional Amounts in those provisions where such express mention is not made. 
 7. Change of Control Triggering Event. Upon the
occurrence of a Change of Control Triggering Event, unless the Company has redeemed this Security or the Company has defeased this Security or satisfied and discharged this Security, the holder of this Security shall have the right to require that
the Company purchase all or a portion (such principal amount to be equal to €100,000 or any integral multiple of €1,000 in excess thereof) of this Security at a purchase price equal to 101% of the aggregate principal amount repurchased
plus accrued and unpaid interest, if any, on the amount to be repurchased up to but excluding the date of purchase. Within 30 days following any Change of Control Triggering Event, the Company shall send, by first class mail, a notice to each
Holder, in accordance with Section 1.5 of the Supplemental Indenture, with a copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. 

8. Denominations, Transfer, Exchange. The Securities are in registered form without coupons in the denominations of €100,000 or
any integral multiple of €1,000 in excess thereof. The transfer of Securities may be registered and Securities may be exchanged as provided in the Indenture. The Securities may be presented for exchange or for registration of transfer (duly
endorsed or with the form of transfer endorsed thereon duly executed if so required by the Company or the Security Registrar) at the office of the Paying Agent or at the office of any transfer agent designated by the Company for such purpose (or
otherwise in accordance with the applicable procedures of Euroclear and Clearstream). No service charge shall be made for any registration of transfer or exchange, but a Securityholder may be required to pay any applicable taxes or other
governmental charges. If the Securities are to be redeemed, the Company shall not be required to: (i) issue, register the transfer of, or exchange any Security during a period beginning at the opening of business 15 days before the day of
mailing of a notice of redemption of less than all of the outstanding Securities and ending at the close of business on the day of such mailing; (ii) register the transfer of or exchange any Security or portions thereof selected for redemption,
in whole or in part, except the unredeemed portions of any such Security being redeemed in part; nor (iii) register the transfer of or exchange of a Security between the applicable record date and the next succeeding Interest Payment Date. 

  
 B-7 

 9. Persons Deemed Owners. The registered Securityholder may be treated as its owner
for all purposes. 
 10. Repayment to the Company. Any funds or Governmental Obligations deposited with any paying agent or the
Trustee, or then held by the Company, in trust for payment of principal of, premium, if any, or interest on the Securities that are not applied but remain unclaimed by the holders of such Securities for at least one year after the date upon which
the principal of, premium, if any, or interest on such Securities shall have respectively become due and payable, shall be repaid to the Company, as applicable, or (if then held by the Company) shall be discharged from such trust. After return to
the Company, Holders entitled to the money or securities must look to the Company, as applicable, for payment as unsecured general creditors. 

11. Amendments, Supplements and Waivers. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and
the modification of the rights and obligations of the Company and the Guarantor and the rights of the Holders of the Securities to be affected under the Indenture at any time by the Company, the Guarantor and the Trustee with the consent of the
Holders of a majority in principal amount of the Securities at the time Outstanding to be affected. The Indenture also contains provisions permitting the Holders of a majority in principal amount of the Securities at the time Outstanding, on behalf
of the Holders of all Securities, to waive compliance by the Company or the Guarantor with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this
Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such
consent or waiver is made upon this Security. 
 12. Defaults and Remedies. If an Event of Default with respect to the Securities
occurs and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of the Securities then Outstanding, by notice in writing to the Company (and to the Trustee if notice is given by such holders), may declare the
entire principal of, premium, if any, and accrued interest, if any, of such Securities due and payable immediately. Subject to the terms of the Indenture, if an Event of Default under the Indenture shall occur and be continuing, the Trustee shall be
under no obligation to exercise any of its rights or powers under the Indenture at the request or direction of any of the holders, unless such holders have offered the Trustee indemnity satisfactory to it. Upon satisfaction of certain conditions set
forth in the Indenture, the holders of a majority in principal amount of the Outstanding Securities shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any
trust or power conferred on the Trustee, with respect to the Securities. 
 13. Trustee, Paying Agent and Security Registrar May Hold
Securities. The Trustee, subject to certain limitations imposed by the TIA, or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if
it were not Trustee, paying agent or Security Registrar. 

  
 B-8 

 14. No Recourse Against Others. No recourse under or upon any obligation, covenant or
agreement of the Indenture, or of any Security, or for any claim based thereon or otherwise in respect hereof or thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or the
Guarantor or of any predecessor or successor corporation, either directly or through the Company or the Guarantor or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement
of any assessment or penalty or otherwise; it being expressly understood that the Indenture and the obligations issued hereunder and thereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or
shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or the Guarantor or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness authorized by the
Indenture, or under or by reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in
equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of the indebtedness authorized by the Indenture, or under or by
reason of the obligations, covenants or agreements contained in the Indenture or in the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the acceptance of the Securities. 

15. Discharge of Indenture. The Indenture contains certain provisions pertaining to discharge and defeasance, which provisions shall
for all purposes have the same effect as if set forth herein. 
 16. Authentication. This Security shall not be valid until the
Trustee signs the certificate of authentication attached to the other side of this Security. 
 17. Guarantee. This Security is fully
and unconditionally guaranteed by the Guarantor, as provided in Article XIV of the Base Indenture. 
 18. Abbreviations. Customary
abbreviations may be used in the name of a Securityholder or an assignee, such as: TEN COM(= tenants in common), TEN ENT (=tenants by the entireties), JT TEN(= joint tenants with right of survivorship and not as tenants in common), CUST
(=Custodian), and U/G/M/A(= Uniform Gifts to Minors Act). 
 19. Governing Law. The Base Indenture, the Supplemental Indenture and
this Security shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

  
 B-9 

 ASSIGNMENT FORM 

To assign this Security, fill in the form below: (I) or (we) assign and transfer this Security to 

 
  

(Insert assignee’s soc. sec. or tax I.D. no.) 
  

 
  

 
  

 
  

 

	
	(Print or type assignee’s name, address and zip code)

 and irrevocably appoint ______________________________________________________________________________ agent to
transfer this Security on the books of the Company. The agent may substitute another to act for him. 
 Date:
                                       
      
  

	
	Your Signature ______________________________
	 _______
 (Sign exactly as your name appears on
the face of this Security)

 Signature Guarantee:
                                       
      

  
 B-10 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Security purchased by the Company pursuant to Section 1.5 of the Supplemental Indenture, check the box:

  

	☐	 1.5 Change of Control Triggering Event 

If you want to elect to have only part of this Security purchased by the Company pursuant to Section 1.5 of the Supplemental Indenture,
state the amount: €_______________________ 
  

			
	 Date:
                                         
       
	  	 Your Signature__________________________________

		  	 ________

(Sign exactly as your name appears on the face of

		  	 this Security)

 Tax I.D. Number: __________________ 

Signature Guarantee: _________________________ 

(Signature must be guaranteed by a 

participant in a recognized signature 

guarantee medallion program) 

  
 B-11 

 NOTATION OF GUARANTEE 

For value received, Thermo Fisher Scientific Inc. hereby absolutely, unconditionally and irrevocably guarantees to the holder of this Security
the payment of principal of, premium, if any, and interest on, the Security upon which this Guarantee is set forth in the amounts and at the time when due and payable whether by declaration thereof, or otherwise, and interest on the overdue
principal and interest, if any, of such Security, if lawful, to the holder of such Security and the Trustee on behalf of the Holders, all in accordance with and subject to the terms and limitations of such Security and Article XIV of the
Indenture. This Guarantee will not become effective until the Trustee or Authenticating Agent duly executes the certificate of authentication on this Security and until this Security has been effectuated for and on behalf of the Common Safekeeper.
This Guarantee shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict of law principles thereof. 

Dated: [ ] 
  

			
	THERMO FISHER SCIENTIFIC INC.
		
	By:	 	
                

	Name:	 	
	Title:	 	

  
 B-12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]